CINXE.COM

<!DOCTYPE html> <html lang="en-US" class="no-js"> <head> <meta charset="UTF-8"> <meta name="SKYPE_TOOLBAR" content="SKYPE_TOOLBAR_PARSER_COMPATIBLE" /> <link rel="profile" href="https://gmpg.org/xfn/11"> <meta name="viewport" content="width=device-width, initial-scale=1"> <script> 'use strict'; (function(html){html.className = html.className.replace(/\bno-js\b/,'js')})(document.documentElement);</script> <meta name='robots' content='noindex, follow' /> <style>img:is([sizes="auto" i], [sizes^="auto," i]) { contain-intrinsic-size: 3000px 1500px }</style>  <title>March 2024 - Lexaria Bioscience</title> <meta property="og:locale" content="en_US" /> <meta property="og:type" content="website" /> <meta property="og:title" content="March 2024 - Lexaria Bioscience" /> <meta property="og:url" content="https://lexariabioscience.com/2024/03/" /> <meta property="og:site_name" content="Lexaria Bioscience" /> <meta name="twitter:card" content="summary_large_image" /> <script type="application/ld+json" class="yoast-schema-graph">{"@context":"https://schema.org","@graph":[{"@type":"CollectionPage","@id":"https://lexariabioscience.com/2024/03/","url":"https://lexariabioscience.com/2024/03/","name":"March 2024 - Lexaria Bioscience","isPartOf":{"@id":"https://lexariabioscience.com/#website"},"breadcrumb":{"@id":"https://lexariabioscience.com/2024/03/#breadcrumb"},"inLanguage":"en-US"},{"@type":"BreadcrumbList","@id":"https://lexariabioscience.com/2024/03/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://lexariabioscience.com/"},{"@type":"ListItem","position":2,"name":"Archives for March 2024"}]},{"@type":"WebSite","@id":"https://lexariabioscience.com/#website","url":"https://lexariabioscience.com/","name":"Lexaria Bioscience","description":"","publisher":{"@id":"https://lexariabioscience.com/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https://lexariabioscience.com/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https://lexariabioscience.com/#organization","name":"Lexaria Bioscience","url":"https://lexariabioscience.com/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https://lexariabioscience.com/#/schema/logo/image/","url":"http://lexariabioscience.com/wp-content/uploads/2022/03/Lexaria_Bioscience_Logo_Dark_WEB.png","contentUrl":"http://lexariabioscience.com/wp-content/uploads/2022/03/Lexaria_Bioscience_Logo_Dark_WEB.png","width":418,"height":220,"caption":"Lexaria Bioscience"},"image":{"@id":"https://lexariabioscience.com/#/schema/logo/image/"}}]}</script>  <link rel='dns-prefetch' href='//www.googletagmanager.com' /> <link rel='dns-prefetch' href='//fonts.googleapis.com' /> <link href='//hb.wpmucdn.com' rel='preconnect' /> <link href="https://fonts.googleapis.com" rel='preconnect' /> <link href='//fonts.gstatic.com' crossorigin='' rel='preconnect' /> <link rel="alternate" type="application/rss+xml" title="Lexaria Bioscience » Feed" href="https://lexariabioscience.com/feed/" /> <link rel="alternate" type="application/rss+xml" title="Lexaria Bioscience » Comments Feed" href="https://lexariabioscience.com/comments/feed/" /> <script> /* <![CDATA[ */ window._wpemojiSettings = {"baseUrl":"https:\/\/s.w.org\/images\/core\/emoji\/15.0.3\/72x72\/","ext":".png","svgUrl":"https:\/\/s.w.org\/images\/core\/emoji\/15.0.3\/svg\/","svgExt":".svg","source":{"concatemoji":"https:\/\/lexariabioscience.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=6.7.1"}}; /*! This file is auto-generated */ !function(i,n){var o,s,e;function c(e){try{var t={supportTests:e,timestamp:(new Date).valueOf()};sessionStorage.setItem(o,JSON.stringify(t))}catch(e){}}function p(e,t,n){e.clearRect(0,0,e.canvas.width,e.canvas.height),e.fillText(t,0,0);var t=new Uint32Array(e.getImageData(0,0,e.canvas.width,e.canvas.height).data),r=(e.clearRect(0,0,e.canvas.width,e.canvas.height),e.fillText(n,0,0),new Uint32Array(e.getImageData(0,0,e.canvas.width,e.canvas.height).data));return t.every(function(e,t){return e===r[t]})}function u(e,t,n){switch(t){case"flag":return n(e,"\ud83c\udff3\ufe0f\u200d\u26a7\ufe0f","\ud83c\udff3\ufe0f\u200b\u26a7\ufe0f")?!1:!n(e,"\ud83c\uddfa\ud83c\uddf3","\ud83c\uddfa\u200b\ud83c\uddf3")&&!n(e,"\ud83c\udff4\udb40\udc67\udb40\udc62\udb40\udc65\udb40\udc6e\udb40\udc67\udb40\udc7f","\ud83c\udff4\u200b\udb40\udc67\u200b\udb40\udc62\u200b\udb40\udc65\u200b\udb40\udc6e\u200b\udb40\udc67\u200b\udb40\udc7f");case"emoji":return!n(e,"\ud83d\udc26\u200d\u2b1b","\ud83d\udc26\u200b\u2b1b")}return!1}function f(e,t,n){var r="undefined"!=typeof WorkerGlobalScope&&self instanceof WorkerGlobalScope?new OffscreenCanvas(300,150):i.createElement("canvas"),a=r.getContext("2d",{willReadFrequently:!0}),o=(a.textBaseline="top",a.font="600 32px Arial",{});return e.forEach(function(e){o[e]=t(a,e,n)}),o}function t(e){var t=i.createElement("script");t.src=e,t.defer=!0,i.head.appendChild(t)}"undefined"!=typeof Promise&&(o="wpEmojiSettingsSupports",s=["flag","emoji"],n.supports={everything:!0,everythingExceptFlag:!0},e=new Promise(function(e){i.addEventListener("DOMContentLoaded",e,{once:!0})}),new Promise(function(t){var n=function(){try{var e=JSON.parse(sessionStorage.getItem(o));if("object"==typeof e&&"number"==typeof e.timestamp&&(new Date).valueOf()<e.timestamp+604800&&"object"==typeof e.supportTests)return e.supportTests}catch(e){}return null}();if(!n){if("undefined"!=typeof Worker&&"undefined"!=typeof OffscreenCanvas&&"undefined"!=typeof URL&&URL.createObjectURL&&"undefined"!=typeof Blob)try{var e="postMessage("+f.toString()+"("+[JSON.stringify(s),u.toString(),p.toString()].join(",")+"));",r=new Blob([e],{type:"text/javascript"}),a=new Worker(URL.createObjectURL(r),{name:"wpTestEmojiSupports"});return void(a.onmessage=function(e){c(n=e.data),a.terminate(),t(n)})}catch(e){}c(n=f(s,u,p))}t(n)}).then(function(e){for(var t in e)n.supports[t]=e[t],n.supports.everything=n.supports.everything&&n.supports[t],"flag"!==t&&(n.supports.everythingExceptFlag=n.supports.everythingExceptFlag&&n.supports[t]);n.supports.everythingExceptFlag=n.supports.everythingExceptFlag&&!n.supports.flag,n.DOMReady=!1,n.readyCallback=function(){n.DOMReady=!0}}).then(function(){return e}).then(function(){var e;n.supports.everything||(n.readyCallback(),(e=n.source||{}).concatemoji?t(e.concatemoji):e.wpemoji&&e.twemoji&&(t(e.twemoji),t(e.wpemoji)))}))}((window,document),window._wpemojiSettings); /* ]]> */ </script> <link rel='stylesheet' id='cnss_font_awesome_css-css' href='https://lexariabioscience.com/wp-content/plugins/easy-social-icons/css/font-awesome/css/all.min.css?ver=5.7.2' media='all' /> <link rel='stylesheet' id='cnss_font_awesome_v4_shims-css' href='https://lexariabioscience.com/wp-content/plugins/easy-social-icons/css/font-awesome/css/v4-shims.min.css?ver=5.7.2' media='all' /> <link rel='stylesheet' id='cnss_css-css' href='https://lexariabioscience.com/wp-content/plugins/easy-social-icons/css/cnss.css?ver=1.0' media='all' /> <style id='wp-emoji-styles-inline-css'> img.wp-smiley, img.emoji { display: inline !important; border: none !important; box-shadow: none !important; height: 1em !important; width: 1em !important; margin: 0 0.07em !important; vertical-align: -0.1em !important; background: none !important; padding: 0 !important; } </style> <link rel='stylesheet' id='wp-block-library-css' href='https://lexariabioscience.com/wp-includes/css/dist/block-library/style.min.css?ver=6.7.1' media='all' /> <style id='classic-theme-styles-inline-css'> /*! This file is auto-generated */ .wp-block-button__link{color:#fff;background-color:#32373c;border-radius:9999px;box-shadow:none;text-decoration:none;padding:calc(.667em + 2px) calc(1.333em + 2px);font-size:1.125em}.wp-block-file__button{background:#32373c;color:#fff;text-decoration:none} </style> <style id='global-styles-inline-css'> :root{--wp--preset--aspect-ratio--square: 1;--wp--preset--aspect-ratio--4-3: 4/3;--wp--preset--aspect-ratio--3-4: 3/4;--wp--preset--aspect-ratio--3-2: 3/2;--wp--preset--aspect-ratio--2-3: 2/3;--wp--preset--aspect-ratio--16-9: 16/9;--wp--preset--aspect-ratio--9-16: 9/16;--wp--preset--color--black: #000000;--wp--preset--color--cyan-bluish-gray: #abb8c3;--wp--preset--color--white: #ffffff;--wp--preset--color--pale-pink: #f78da7;--wp--preset--color--vivid-red: #cf2e2e;--wp--preset--color--luminous-vivid-orange: #ff6900;--wp--preset--color--luminous-vivid-amber: #fcb900;--wp--preset--color--light-green-cyan: #7bdcb5;--wp--preset--color--vivid-green-cyan: #00d084;--wp--preset--color--pale-cyan-blue: #8ed1fc;--wp--preset--color--vivid-cyan-blue: #0693e3;--wp--preset--color--vivid-purple: #9b51e0;--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple: linear-gradient(135deg,rgba(6,147,227,1) 0%,rgb(155,81,224) 100%);--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan: linear-gradient(135deg,rgb(122,220,180) 0%,rgb(0,208,130) 100%);--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange: linear-gradient(135deg,rgba(252,185,0,1) 0%,rgba(255,105,0,1) 100%);--wp--preset--gradient--luminous-vivid-orange-to-vivid-red: linear-gradient(135deg,rgba(255,105,0,1) 0%,rgb(207,46,46) 100%);--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray: linear-gradient(135deg,rgb(238,238,238) 0%,rgb(169,184,195) 100%);--wp--preset--gradient--cool-to-warm-spectrum: linear-gradient(135deg,rgb(74,234,220) 0%,rgb(151,120,209) 20%,rgb(207,42,186) 40%,rgb(238,44,130) 60%,rgb(251,105,98) 80%,rgb(254,248,76) 100%);--wp--preset--gradient--blush-light-purple: linear-gradient(135deg,rgb(255,206,236) 0%,rgb(152,150,240) 100%);--wp--preset--gradient--blush-bordeaux: linear-gradient(135deg,rgb(254,205,165) 0%,rgb(254,45,45) 50%,rgb(107,0,62) 100%);--wp--preset--gradient--luminous-dusk: linear-gradient(135deg,rgb(255,203,112) 0%,rgb(199,81,192) 50%,rgb(65,88,208) 100%);--wp--preset--gradient--pale-ocean: linear-gradient(135deg,rgb(255,245,203) 0%,rgb(182,227,212) 50%,rgb(51,167,181) 100%);--wp--preset--gradient--electric-grass: linear-gradient(135deg,rgb(202,248,128) 0%,rgb(113,206,126) 100%);--wp--preset--gradient--midnight: linear-gradient(135deg,rgb(2,3,129) 0%,rgb(40,116,252) 100%);--wp--preset--font-size--small: 13px;--wp--preset--font-size--medium: 20px;--wp--preset--font-size--large: 36px;--wp--preset--font-size--x-large: 42px;--wp--preset--spacing--20: 0.44rem;--wp--preset--spacing--30: 0.67rem;--wp--preset--spacing--40: 1rem;--wp--preset--spacing--50: 1.5rem;--wp--preset--spacing--60: 2.25rem;--wp--preset--spacing--70: 3.38rem;--wp--preset--spacing--80: 5.06rem;--wp--preset--shadow--natural: 6px 6px 9px rgba(0, 0, 0, 0.2);--wp--preset--shadow--deep: 12px 12px 50px rgba(0, 0, 0, 0.4);--wp--preset--shadow--sharp: 6px 6px 0px rgba(0, 0, 0, 0.2);--wp--preset--shadow--outlined: 6px 6px 0px -3px rgba(255, 255, 255, 1), 6px 6px rgba(0, 0, 0, 1);--wp--preset--shadow--crisp: 6px 6px 0px rgba(0, 0, 0, 1);}:where(.is-layout-flex){gap: 0.5em;}:where(.is-layout-grid){gap: 0.5em;}body .is-layout-flex{display: flex;}.is-layout-flex{flex-wrap: wrap;align-items: center;}.is-layout-flex > :is(*, div){margin: 0;}body .is-layout-grid{display: grid;}.is-layout-grid > :is(*, div){margin: 0;}:where(.wp-block-columns.is-layout-flex){gap: 2em;}:where(.wp-block-columns.is-layout-grid){gap: 2em;}:where(.wp-block-post-template.is-layout-flex){gap: 1.25em;}:where(.wp-block-post-template.is-layout-grid){gap: 1.25em;}.has-black-color{color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-color{color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-color{color: var(--wp--preset--color--white) !important;}.has-pale-pink-color{color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-color{color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-color{color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-color{color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-color{color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-color{color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-color{color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-color{color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-color{color: var(--wp--preset--color--vivid-purple) !important;}.has-black-background-color{background-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-background-color{background-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-background-color{background-color: var(--wp--preset--color--white) !important;}.has-pale-pink-background-color{background-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-background-color{background-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-background-color{background-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-background-color{background-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-background-color{background-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-background-color{background-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-background-color{background-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-background-color{background-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-background-color{background-color: var(--wp--preset--color--vivid-purple) !important;}.has-black-border-color{border-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-border-color{border-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-border-color{border-color: var(--wp--preset--color--white) !important;}.has-pale-pink-border-color{border-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-border-color{border-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-border-color{border-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-border-color{border-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-border-color{border-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-border-color{border-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-border-color{border-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-border-color{border-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-border-color{border-color: var(--wp--preset--color--vivid-purple) !important;}.has-vivid-cyan-blue-to-vivid-purple-gradient-background{background: var(--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple) !important;}.has-light-green-cyan-to-vivid-green-cyan-gradient-background{background: var(--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan) !important;}.has-luminous-vivid-amber-to-luminous-vivid-orange-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange) !important;}.has-luminous-vivid-orange-to-vivid-red-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-orange-to-vivid-red) !important;}.has-very-light-gray-to-cyan-bluish-gray-gradient-background{background: var(--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray) !important;}.has-cool-to-warm-spectrum-gradient-background{background: var(--wp--preset--gradient--cool-to-warm-spectrum) !important;}.has-blush-light-purple-gradient-background{background: var(--wp--preset--gradient--blush-light-purple) !important;}.has-blush-bordeaux-gradient-background{background: var(--wp--preset--gradient--blush-bordeaux) !important;}.has-luminous-dusk-gradient-background{background: var(--wp--preset--gradient--luminous-dusk) !important;}.has-pale-ocean-gradient-background{background: var(--wp--preset--gradient--pale-ocean) !important;}.has-electric-grass-gradient-background{background: var(--wp--preset--gradient--electric-grass) !important;}.has-midnight-gradient-background{background: var(--wp--preset--gradient--midnight) !important;}.has-small-font-size{font-size: var(--wp--preset--font-size--small) !important;}.has-medium-font-size{font-size: var(--wp--preset--font-size--medium) !important;}.has-large-font-size{font-size: var(--wp--preset--font-size--large) !important;}.has-x-large-font-size{font-size: var(--wp--preset--font-size--x-large) !important;} :where(.wp-block-post-template.is-layout-flex){gap: 1.25em;}:where(.wp-block-post-template.is-layout-grid){gap: 1.25em;} :where(.wp-block-columns.is-layout-flex){gap: 2em;}:where(.wp-block-columns.is-layout-grid){gap: 2em;} :root :where(.wp-block-pullquote){font-size: 1.5em;line-height: 1.6;} </style> <link rel='stylesheet' id='contact-form-7-css' href='https://lexariabioscience.com/wp-content/plugins/contact-form-7/includes/css/styles.css?ver=6.0' media='all' /> <link rel='stylesheet' id='font-awesome-css' href='https://lexariabioscience.com/wp-content/plugins/themestek-labtechco-extras/icon-picker/icon-libraries/font-awesome/css/font-awesome.min.css?ver=6.7.1' media='all' /> <link rel='stylesheet' id='themify-css' href='https://lexariabioscience.com/wp-content/plugins/themestek-labtechco-extras/icon-picker/icon-libraries/themify-icons/themify-icons.css?ver=6.7.1' media='all' /> <link rel='stylesheet' id='sgicon-css' href='https://lexariabioscience.com/wp-content/plugins/themestek-labtechco-extras/icon-picker/icon-libraries/stroke-gap-icons/style.css?ver=6.7.1' media='all' /> <link rel='stylesheet' id='vc_linecons-css' href='https://lexariabioscience.com/wp-content/plugins/js_composer/assets/css/lib/vc-linecons/vc_linecons_icons.min.css?ver=7.7.2' media='all' /> <link rel='stylesheet' id='ts_labtechco_business_icon-css' href='https://lexariabioscience.com/wp-content/plugins/themestek-labtechco-extras/icon-picker/icon-libraries/ts-lab-icons/font/flaticon.css?ver=6.7.1' media='all' /> <link rel='stylesheet' id='ts-cs-google-fonts-css' href='//fonts.googleapis.com/css?family=Poppins%3A300%2C400%2C500%2C600%2C700%7CArimo%3A400%7CVollkorn%3A700%7CRoboto+Condensed%3A300%2C300italic%2C400%2Citalic%2C700%2C700italic%7CRoboto%3A500&ver=1.0.0' media='all' /> <link rel='stylesheet' id='ts-base-icons-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/libraries/ts-labtechco-icons/css/ts-labtechco-icons.css?ver=6.7.1' media='all' /> <link rel='stylesheet' id='perfect-scrollbar-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/libraries/perfect-scrollbar/perfect-scrollbar.min.css?ver=6.7.1' media='all' /> <link rel='stylesheet' id='chrisbracco-tooltip-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/libraries/chrisbracco-tooltip/chrisbracco-tooltip.min.css?ver=6.7.1' media='all' /> <link rel='stylesheet' id='multi-columns-row-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/css/multi-columns-row.css?ver=6.7.1' media='all' /> <link rel='stylesheet' id='ts-select2-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/libraries/select2/select2.min.css?ver=6.7.1' media='all' /> <link rel='stylesheet' id='flexslider-css' href='https://lexariabioscience.com/wp-content/plugins/js_composer/assets/lib/vendor/node_modules/flexslider/flexslider.min.css?ver=7.7.2' media='all' /> <link rel='stylesheet' id='slick-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/libraries/slick/slick.css?ver=6.7.1' media='all' /> <link rel='stylesheet' id='slick-theme-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/libraries/slick/slick-theme.css?ver=6.7.1' media='all' /> <link rel='stylesheet' id='prettyphoto-css' href='https://lexariabioscience.com/wp-content/plugins/js_composer/assets/lib/vendor/prettyphoto/css/prettyPhoto.min.css?ver=7.7.2' media='all' /> <link rel='stylesheet' id='bootstrap-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/css/bootstrap.min.css?ver=6.7.1' media='all' /> <link rel='stylesheet' id='bootstrap-theme-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/css/bootstrap-theme.min.css?ver=6.7.1' media='all' /> <link rel='stylesheet' id='labtechco-core-style-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/css/core.min.css?ver=6.7.1' media='all' /> <link rel='stylesheet' id='js_composer_front-css' href='https://lexariabioscience.com/wp-content/plugins/js_composer/assets/css/js_composer.min.css?ver=7.7.2' media='all' /> <link rel='stylesheet' id='labtechco-master-style-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/css/master.min.css?ver=6.7.1' media='all' /> <link rel='stylesheet' id='labtechco-responsive-style-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/css/responsive.min.css?ver=6.7.1' media='all' /> <link rel='stylesheet' id='tste-labtechco-theme-style-css' href='https://lexariabioscience.com/wp-admin/admin-ajax.php?action=themestek_theme_css&ver=6.7.1' media='all' /> <script src="https://lexariabioscience.com/wp-includes/js/jquery/jquery.min.js?ver=3.7.1" id="jquery-core-js"></script> <script src="https://lexariabioscience.com/wp-includes/js/jquery/jquery-migrate.min.js?ver=3.4.1" id="jquery-migrate-js"></script> <script src="https://lexariabioscience.com/wp-content/plugins/easy-social-icons/js/cnss.js?ver=1.0" id="cnss_js-js"></script> <script src="https://lexariabioscience.com/wp-content/plugins/b2i-investor-tools/js/wb_script.js?ver=1.0.7.8" id="whistleblower-js"></script> <script src="https://lexariabioscience.com/wp-content/plugins/themestek-labtechco-extras/js/jquery-resize.min.js?ver=6.7.1" id="jquery-resize-js"></script>   <script src="https://www.googletagmanager.com/gtag/js?id=GT-NSVFNVV" id="google_gtagjs-js" async></script> <script id="google_gtagjs-js-after"> /* <![CDATA[ */ window.dataLayer = window.dataLayer || [];function gtag(){dataLayer.push(arguments);} gtag("set","linker",{"domains":["lexariabioscience.com"]}); gtag("js", new Date()); gtag("set", "developer_id.dZTNiMT", true); gtag("config", "GT-NSVFNVV"); /* ]]> */ </script>  <script></script><link rel="https://api.w.org/" href="https://lexariabioscience.com/wp-json/" /><link rel="EditURI" type="application/rsd+xml" title="RSD" href="https://lexariabioscience.com/xmlrpc.php?rsd" /> <meta name="generator" content="WordPress 6.7.1" />  <style> .investor-menu.sticky-nav {position: fixed; left: 0; right: 0; margin-left: auto; margin-right: auto; background-color: transparent !important; width: 100%; z-index: 999; top: 60px;} .investor-menu.sticky-nav #menu-investors {background-color: #3A5DAE !important;} .investor-menu.sticky-nav .container {padding-left: 0; padding-right: 0;}</style>   <style> @media (max-width:844px) { div.investor-menu ul.menu li ul.sub-menu {display: block !important;} ul.sub-menu li {min-width: 100% !important; display: block !important; padding: 5px 0px;} ul.sub-menu {background: transparent !important; padding-left: 30px !important; margin-top: 5px !important;} .investor-menu li a {padding: 0 !important;} .investor-menu li {padding: 5px 0px;} .team-layout3.dir-item-wrap {min-width: 100%;} .team-layout3 .modal-window {min-width: 100%;} .news-right-btn {text-align: left !important;} .b2iHeadLinesHeadlineCell.b2iPlugInHeadLinesHeadlineCell {padding-bottom: 0 !important;} .full-row-grey .vc_row.container {max-width: 90%;} .latest-annual-section {text-align: center;} .latest-annual-section .SECLayout22PDF-formLinks {text-align: center !important;} .email-alerts-section h3 {text-align: center;} .company-overview-section h3 {line-height: 1.2em;} .company-overview-section .btn {min-width: 100%; margin-bottom: 5px;} }</style>   <style> #LibStoryDiv a {text-decoration: underline;} /* Contact */ @media (min-width:844px) { #b2iContact .b2iFormLabel {min-width: 100%; clear: both;} #b2iContact input, #b2iContact select, #b2iContact textarea {min-width: 100%; min-height: 45px;} #b2iContact #ContactEmail, #b2iContact #ContactCompany, #b2iContact #ContactMessage {min-width: 98% !important;} #b2iContact #b2iContactFirstNameRow, #b2iContact #b2iContactLastNameRow, #b2iContact #b2iContactRoleRow, #b2iContact #b2iContactPhoneRow {width: 48%; clear: none; display: inline-block;} #b2iContact #b2iContactFirstNameRow, #b2iContact #b2iContactRoleRow {margin-right: 1.5% !important;} #b2iContact #b2iContactSubmit {min-width: 200px; margin-top: 20px; margin-bottom: 20px;} #b2iContact .b2iFormLabel {font-weight:bold; margin-bottom: 5px; margin-top: 10px;} } @media (max-width:844px) { #b2iContact input, #b2iContact select, #b2iContact textarea {min-width: 100%; min-height: 45px;} #b2iContact #ContactEmail, #b2iContact #ContactCompany, #b2iContact #ContactMessage {min-width: 100% !important;} #b2iContact #b2iContactSubmit {margin-top: 20px; margin-bottom: 20px;} } #b2iContactSubmit {border: 1px solid #000; background: transparent; color: #000; font-size: 18px; cursor: pointer;} /* Email signup */ @media (min-width:844px) { #b2iEmailSignUp {width: 100%;} .b2iEmailDiv, .b2iFirstNameDiv, .b2iLastNameDiv, .b2iCompanyDiv {display: inline-block; width: 49%;} .b2iEmailInput {min-width: 95%;} }</style>   <style> .single .ts-titlebar-main-inner .entry-title {font-size: 30px; line-height: 1.3em;} .ir-contact-3-col {font-size: 16px !important;} @media (min-width:844px) { #LibStoryContainer {margin-top: 50px;} .investor-menu a {padding: 18px 8px !important; } .sub-menu {background: #f5f5f5 !important; box-shadow: 0 6px 12px rgba(0,0,0,.175);} .sub-menu a {color: #031b4e !important;} .sub-menu li {min-width: 100%; border-bottom: 1px solid #ddd;} .sub-menu .current-menu-item {background: #FFF !important;} .view-all-button {background: ##EBEFF7 !important; text-align: center; margin-top: -80px; padding: 0 0 50px 0px!important;} .view-all-button .vc_row.container .btn {margin-bottom: -30px !important;} } @media (max-width: 844px) { .view-all-button {background: ##EBEFF7 !important; text-align: center; margin-top: -120px; padding: 0 0 50px 0px!important;} .view-all-button .vc_row.container .btn {margin-bottom: -30px !important;} .page-id-8559 #DocItem76967, .page-id-8703 #DocItem76967 {min-width: 100% !important;} .DocItemImage {padding: 0 !important;} #DocItemTitle76967, #DocItemTitle76968 {text-align: center;} } #b2iLibNav {margin-top: 50px;} #b2iLibNav a {text-decoration: underline;} /* Tabs */ .vc_tta-tabs-list {border-bottom: 2px solid #3A5DAE !important;} .vc_tta-tabs-list .vc_tta-tab {color: #031b4e; border-left:2px solid #3A5DAE; border-top: 2px solid #3A5DAE; border-right: 2px solid #3A5DAE;} .vc_tta-tabs-list .vc_tta-tab.vc_active span {color: #FFF;} .vc_tta-tabs-list .vc_tta-tab a {border-radius: 0 !important;} .vc_tta-tabs-list .vc_tta-tab.vc_active, .vc_tta-tabs-list .vc_tta-tab.vc_active a {background: #3A5DAE !important;} #DocItem76968 img {width: 100%;} .DocItemImage {width: 100% !important; max-width: 100% !important;} .DocItem8 {padding: 0 !important; margin: 0 !important; max-width: 100% !important; width: 100% !important;} #DocItemTitle76968 { background: #3A5DAE; padding: 15px 0px; } #DocItemTitle76968 a { color: #FFF; } .page-id-8559 #DocItem76967, .page-id-8703 #DocItem76967 {min-width: 350px;} #DocItem76967 img {width: 100%;} #DocItem76967 {min-width: 100%; padding: 0; margin: 0;} #DocItemTitle76967 {background: #3A5DAE; padding: 15px 0px;} #DocItemTitle76967 a {color: #FFF;} .smaller-h3 h3 {font-size: 28px !important; } #press-releases .b2iLibToolsContainer select, #press-releases .b2iLibToolsContainer input {width: auto;} #press-releases #B2iLibSearchButton {margin-left: 5px;} .modal-dialog .dir-item-name, .modal-dialog .dir-item-title-text {line-height: 1.3em;} .amChartsPeriodSelectorButtonDiv {text-align: center;} .amChartsPeriodSelectorButtonDiv input[type="button"] {padding: 5px 10px; margin: 0 3px;} .team-layout3.dir-item-wrap {width: 23%;} .dir-item-photo-container img {min-width: 100%;} .dir-item-wrap_name-container, .team-layout3 .modal-content__header {background: #3A5DAE !important;} .dir-item-name {font-size: 15px;} .modal-content .dir-item-photo img {padding: 10px 10px 20px 10px;} .modal-content .dir-item-bio {font-size: 17px;} .modal-dialog, .modal-content {box-shadow: none !important;} .btn.ShowCaseLinkImage {color: #FFF; font-size: 16px; padding: 15px 35px; border: none;} #b2iSecForm select {width: auto;} #b2iSection23038 {padding-left: 0 !important; padding-right: 0 !important;} #b2iQuoteID10 .b2iClientQuote .b2iClientQuoteLabel {color: #333 !important;} .b2iPrimaryButton.b2iButton.b2iSecSearch.xxsmall {max-height: 30px; margin-left: 10px;} #b2iHistoricQuoteForm input {width: auto;} #b2iHistoricQuoteForm {padding-bottom: 30px;} .b2iSECtopSelectCell2 .select2 {width: auto !important; min-width: 250px;} .b2iSECtopSelect, .b2iSECtopSelecttd, .b2iSECtopSelect tr, .b2iSECtopTitleTable, .b2iSECtopTitleTable td, .b2iSECtopTitleTable tr, .b2iSECtopTitleTable th {border: none !important;} #b2iSecTop {margin-top: 20px;} .FilterLabel {margin-right: 5px; margin-left: 20px;} .b2iHeader.active, .b2iHeader:hover {background-color: #3A5DAE !important; color: #FFF; font-weight: 600;} .ir-content .document-report span, .ir-content .document-report {font-size: 19px;} .ir-content .document-report {padding-top: 20px;} .SECLayout16.SECItembutton-link a {background: #3A5DAE !important; font-size: 16px !important; font-weight: 600; padding: 15px 35px !important; box-shadow: none !important; } .b2iFinancialsHeader {line-height: 1.4em; margin-bottom: 20px;} .B2iFinancialsContainer, .B2iFinancialsContainer div, .B2iFinancialsContainer a {color: #333 !important;} .docDetails-col .DocItemTitle {margin-bottom: 5px;} #b2iEmailSignUp label {margin-left: 5px;} #b2iEmailSignUp input {border-radius: 0;} #b2iEmailList .b2iEmailFieldset {padding: 5px;} .ir-content .a-input-text, .ir-content .a-input-select, .ir-content .b2iFormRow input:not(.b2iEmailAlertCheckbox), .ir-content .b2iTextbox:not(.b2iEmailAlertCheckbox), .ir-content .InputDate, .ir-content #b2iSearchbox, .ir-content .b2iSelect {border-color: #3A5DAE; border-radius:0;} .ir-content {font-size: 19px;} .b2iPlugInHeadlinesDate {margin-top: 20px; margin-bottom: 2px !important;} .b2iLibToolsContainer .select2-selection__rendered {padding-left: 15px !important;} .ir-content .main-holder .site #content table.cart td.actions .input-text, .ir-content textarea, input[type="text"], .ir-content input[type="password"], .ir-content input[type="datetime"], .ir-content input[type="datetime-local"], .ir-content input[type="date"], .ir-content input[type="month"], .ir-content input[type="time"], .ir-content input[type="week"], .ir-content input[type="number"], .ir-content input[type="email"], .ir-content input[type="url"], .ir-content input[type="search"], .ir-content input[type="tel"], .ir-content input[type="color"], .ir-content .uneditable-input, .ir-content select {border: 1px solid #3A5DAE !important;} #b2iLibSearch input {margin-bottom: 10px; margin-top: 10px;} .ir-content button, .ir-content input[type="submit"], .ir-content input[type="button"], .ir-content input[type="reset"] {background-color: #3A5DAE;} .ir-content h3 {font-weight: 600; color: #031b4e; font-size: 36px; letter-spacing: -0.01em; margin-bottom: 20px; margin-top: 40px;} .ir-content, .ir-content a {color: #031b4e;} .current-menu-ancestor {background-color: rgba(0,0,0,0.3);} .inline-btns .btn {display: inline-block; margin-right: 4px;} .inline-btns br {display: none;} .page-id-8559 .ts-titlebar-main h1 {position: relative; z-index: 3;} .page-id-8559 .ts-titlebar-main .breadcrumb-wrapper {z-index: 2; position: relative;} .page-id-8559 .ts-titlebar-main:before {content: ''; position: absolute; z-index: 1; width: 100%; top: 0; left: 0; bottom: 0; background: #1B3C92; opacity: .5;} .stock-quote-section {background: #018A17; min-width: 100%; text-align: left; padding: 30px 0px 0px 0px;} .stock-quote-section .container {padding-left: 0 !important; padding-right: 0 !important;} .stock-quote-section .b2iQuote91data-title {color: #FFF; font-size:12px; } .stock-quote-section .b2iQuote91data, .stock-quote-section .data, .stock-quote-section .ChangeStyle {color: #FFF; font-size: 20px; font-weight: 700;} .ir-contacts-section {padding: 80px 0px 0px 0px !important;} .ir-contacts-section .ts-custom-heading {text-align: left;} .ir-contacts-data h3 {font-weight: 700; font-size: 20px; margin-top: 0; margin-bottom: 0; color: #031B4E;} .ir-contacts-data h4 {margin-top: 10px; color: #031B4E;} .ir-contacts-data {font-size: 18px; color: #212529; line-height: 1.3em;} .company-overview-section {padding: 80px 0px !important;} .company-overview-section h3 {font-weight: 600; font-size: 40px; letter-spacing: -0.02em; margin-bottom: 30px; margin-top: 0;} .company-overview-section p {color: #212529;} .company-overview-section .btn {margin-right: 5px; font-size: 15px;} .email-alerts-section h3 {color: #FFF; font-weight: 700; font-size: 40px; margin-top: 0;} .email-alerts-section {color: #FFF; padding: 60px 0px 20px 0px; background-size: cover; } .email-alerts-section p {font-size: 19px; letter-spacing: -0.02em; text-align: center;} .email-alerts-section .btn {color: #FFF; border-color: #FFF;} .email-signup-btn-col {text-align: right;} .latest-financial-results-section {padding: 80px 0px 40px 0px; background: #FFF!important;} .latest-1 .ts-cta3-content-wrapper {min-width: 100%;} .latest-1 .ts-custom-heading {text-align: left;} .latest-1 .flex.flex-third.filing-type {display: block !important; min-width: 100%; text-align: left;} .latest-1 .result-line {text-align: left; padding: 15px 0px !important;} .latest-1 a {color: #3A5DAE !important;} .latest-1 .filing-name {color: #031B4E; margin-top: 30px;} .latest-1 .qedate {color: #031B4E; margin-bottom: 10px;} .latest-1 .qedate span {display: inline-block; font-weight: 500; font-size: 12px;} .latest-1 .EndedSpan2 {margin-left: 5px;} .dots-img img {position: relative; z-index: 9;} .dots-img:after {content: ""; position: absolute; top: -54px; right: -40px; height: 136px; width: 132px; background: url(https://d1io3yog0oux5.cloudfront.net/_860e50159b1afe5949e7e2039c834240/lexariabioscience/files/theme/images/dots.svg) no-repeat center; background-size: 100%;} .dots-img-2 img {position: relative; z-index: 9;} .dots-img-2:after {content: ""; content: ""; position: absolute; bottom: -54px; left: -40px; height: 136px; width: 132px; background: url(https://d1io3yog0oux5.cloudfront.net/_860e50159b1afe5949e7e2039c834240/lexariabioscience/files/theme/images/dots.svg) no-repeat center; background-size: 100%;} .latest-annual-section .container {border-top: solid 1px #ddd; padding-top: 40px !important;} .latest-annual-section {background: #FFF !important; padding-bottom: 50px;} .latest-annual-section h3 {margin-top: 0; font-weight: 700;} .latest-annual-section h4 {margin-top: 10px;} .latest-annual-section h3, .latest-annual-section h4 {color: #031B4E !important;} .SECLayout22PDFItem-link.PDF-link a {color: #3A5DAE !important;} .SECLayout22PDF-formLinks {text-align: right;} .SECLayout22PDFItem-link.PDF-link {background: rgba(0, 0, 0, 0); display: inline-block; font-size: 16px; letter-spacing: normal; font-weight: 600; font-family: "Poppins", sans-serif; line-height: 1; margin-bottom: 5px; background: #FFF !important;border-radius: 0 !important; text-align: center; text-transform: none; white-space: normal; -moz-transition: background-color 0.2s ease, border-color 0.2s ease; -o-transition: background-color 0.2s ease, border-color 0.2s ease; -webkit-transition: background-color 0.2s ease, border-color 0.2s ease; transition: background-color 0.2s ease, border-color 0.2s ease; border: 2px solid #3A5DAE; color: #3A5DAE !important; margin: 0; padding: 15px 35px !important; border-radius: 0; text-decoration: none;} .news-right-btn {text-align: right;} .btn:hover {color: #FFF; background: #3A5DAE;} .btn {background: rgba(0, 0, 0, 0); display: inline-block; font-size: 16px; letter-spacing: normal; font-weight: 600; font-family: "Poppins", sans-serif; line-height: 1; margin-bottom: 5px; text-align: center; text-transform: none; white-space: normal; -moz-transition: background-color 0.2s ease, border-color 0.2s ease; -o-transition: background-color 0.2s ease, border-color 0.2s ease; -webkit-transition: background-color 0.2s ease, border-color 0.2s ease; transition: background-color 0.2s ease, border-color 0.2s ease; border: 2px solid #3A5DAE; color: #3A5DAE; margin: 0; padding: 15px 35px; border-radius: 0; text-decoration: none;} #b2iPlugInHeadLine {padding-left: 0;} #b2iPlugInHeadLine li {list-style: none;} .b2iPlugInHeadlinesDate {margin-bottom: 10px;} .news-2 .b2iLibraryHeadlineLink {font-size: 18px !important; font-weight:400; text-decoration: underline;} .news-2 .b2iPlugInHeadlinesItem {margin-bottom:25px;} .b2iHeadLinesDateCell, .b2iPlugInHeadlinesDate {font-size:12px; text-transform: none; font-weight: 400; color: #031B4E;} .news-2 #b2iLibNav, .news-1 #b2iLibNav {display: none;} .full-row-grey {background: #EBEFF7; padding: 60px 0px; } .full-row-grey .vc_row.container { padding: 30px 30px 30px 30px !important; background: #FFF; } .full-row-grey h3 {font-weight: 700; letter-spacing: -0.01em; font-size: 20px;} .ts-titlebar-main h1 {font-family: 'Poppins' !important; text-transform: none !important; letter-spacing: -0.02em !important;} div.investor-menu li.current-menu-item {background-color: rgba(0,0,0,0.3);} .b2iPressContainer table, .b2iPressContainer tr, .b2iPressContainer td {border: none;} .b2iHeadLinesHeadlineCell a {font-weight: 400; text-decoration: underline; font-size: 26px; line-height: 1.3em;} div.investor-menu {background-color: #3A5DAE !important;} div.investor-menu a {font-size: 13px; font-weight: 700; line-height: 1.4em; letter-spacing: 0;} div.investor-menu li {display: inline-block; float: none; position: relative; text-align: left;} /* Basic styles for the menu container */ div.investor-menu { background-color: #333; position: relative; } /* Style for the main menu items */ div.investor-menu ul.menu { list-style-type: none; margin: 0; padding: 0; display: flex; flex-direction: row; /* Align items horizontally */ } /* Style for individual menu items */ div.investor-menu ul.menu > li { position: relative; } /* Style for links */ div.investor-menu ul.menu > li > a { display: block; color: white; text-align: center; padding: 14px 16px; text-decoration: none; } /* Change color on hover */ div.investor-menu ul.menu > li > a:hover { background-color: #111; } /* Style for the dropdown */ div.investor-menu ul.menu li ul.sub-menu { display: none; position: absolute; background-color: #333; min-width: 160px; z-index: 999; list-style-type: none; margin: 0; padding: 0; } /* Style for dropdown links */ div.investor-menu ul.menu li ul.sub-menu li a { padding: 12px 16px; text-decoration: none; display: block; text-align: left; color: white; } /* Show the dropdown on hover */ div.investor-menu ul.menu li:hover ul.sub-menu { display: block; } /* Hamburger menu styles */ div.investor-menu .hamburger { display: none; font-size: 30px; color: white; padding: 14px 16px; cursor: pointer; } /* Media query for screens 1000px or smaller */ @media screen and (max-width: 1000px) { /* Stack the menu items vertically */ div.investor-menu ul.menu { flex-direction: column; display: none; /* Hide menu by default */ width: 100%; } /* Show the hamburger icon */ div.investor-menu .hamburger { display: block; } /* Show menu when active */ div.investor-menu ul.menu.active { display: flex; } /* Style for links in vertical mode */ div.investor-menu ul.menu > li > a { text-align: left; padding: 12px 16px; } /* Dropdowns in vertical mode */ div.investor-menu ul.menu li ul.sub-menu { position: relative; } } </style>  <style> ul.cnss-social-icon li.cn-fa-icon a{background-color:#3a5dae!important;} ul.cnss-social-icon li.cn-fa-icon a:hover{background-color:#264899!important;color:#ffffff!important;} </style><meta name="generator" content="Site Kit by Google 1.140.0" /><meta name="generator" content="Powered by WPBakery Page Builder - drag and drop page builder for WordPress."/>  <script> /* <![CDATA[ */ ( function( w, d, s, l, i ) { w[l] = w[l] || []; w[l].push( {'gtm.start': new Date().getTime(), event: 'gtm.js'} ); var f = d.getElementsByTagName( s )[0], j = d.createElement( s ), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src = 'https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore( j, f ); } )( window, document, 'script', 'dataLayer', 'GTM-KNPGWSZ' ); /* ]]> */ </script>  <meta name="generator" content="Powered by Slider Revolution 6.5.15 - responsive, Mobile-Friendly Slider Plugin for WordPress with comfortable drag and drop interface." /> <link rel="icon" href="https://lexariabioscience.com/wp-content/uploads/2022/06/cropped-Lexaria_Bioscience_Logo_Square_SocialMedia_A-32x32.png" sizes="32x32" /> <link rel="icon" href="https://lexariabioscience.com/wp-content/uploads/2022/06/cropped-Lexaria_Bioscience_Logo_Square_SocialMedia_A-192x192.png" sizes="192x192" /> <link rel="apple-touch-icon" href="https://lexariabioscience.com/wp-content/uploads/2022/06/cropped-Lexaria_Bioscience_Logo_Square_SocialMedia_A-180x180.png" /> <meta name="msapplication-TileImage" content="https://lexariabioscience.com/wp-content/uploads/2022/06/cropped-Lexaria_Bioscience_Logo_Square_SocialMedia_A-270x270.png" /> <script>function setREVStartSize(e){ //window.requestAnimationFrame(function() { window.RSIW = window.RSIW===undefined ? window.innerWidth : window.RSIW; window.RSIH = window.RSIH===undefined ? window.innerHeight : window.RSIH; try { var pw = document.getElementById(e.c).parentNode.offsetWidth, newh; pw = pw===0 || isNaN(pw) ? window.RSIW : pw; e.tabw = e.tabw===undefined ? 0 : parseInt(e.tabw); e.thumbw = e.thumbw===undefined ? 0 : parseInt(e.thumbw); e.tabh = e.tabh===undefined ? 0 : parseInt(e.tabh); e.thumbh = e.thumbh===undefined ? 0 : parseInt(e.thumbh); e.tabhide = e.tabhide===undefined ? 0 : parseInt(e.tabhide); e.thumbhide = e.thumbhide===undefined ? 0 : parseInt(e.thumbhide); e.mh = e.mh===undefined || e.mh=="" || e.mh==="auto" ? 0 : parseInt(e.mh,0); if(e.layout==="fullscreen" || e.l==="fullscreen") newh = Math.max(e.mh,window.RSIH); else{ e.gw = Array.isArray(e.gw) ? e.gw : [e.gw]; for (var i in e.rl) if (e.gw[i]===undefined || e.gw[i]===0) e.gw[i] = e.gw[i-1]; e.gh = e.el===undefined || e.el==="" || (Array.isArray(e.el) && e.el.length==0)? e.gh : e.el; e.gh = Array.isArray(e.gh) ? e.gh : [e.gh]; for (var i in e.rl) if (e.gh[i]===undefined || e.gh[i]===0) e.gh[i] = e.gh[i-1]; var nl = new Array(e.rl.length), ix = 0, sl; e.tabw = e.tabhide>=pw ? 0 : e.tabw; e.thumbw = e.thumbhide>=pw ? 0 : e.thumbw; e.tabh = e.tabhide>=pw ? 0 : e.tabh; e.thumbh = e.thumbhide>=pw ? 0 : e.thumbh; for (var i in e.rl) nl[i] = e.rl[i]<window.RSIW ? 0 : e.rl[i]; sl = nl[0]; for (var i in nl) if (sl>nl[i] && nl[i]>0) { sl = nl[i]; ix=i;} var m = pw>(e.gw[ix]+e.tabw+e.thumbw) ? 1 : (pw-(e.tabw+e.thumbw)) / (e.gw[ix]); newh = (e.gh[ix] * m) + (e.tabh + e.thumbh); } var el = document.getElementById(e.c); if (el!==null && el) el.style.height = newh+"px"; el = document.getElementById(e.c+"_wrapper"); if (el!==null && el) { el.style.height = newh+"px"; el.style.display = "block"; } } catch(e){ console.log("Failure at Presize of Slider:" + e) } //}); };</script> <noscript><style> .wpb_animate_when_almost_visible { opacity: 1; }</style></noscript></head> <body class="archive date ts-headerstyle-infostack themestek-wide themestek-sidebar-true themestek-sidebar-right wpb-js-composer js-comp-ver-7.7.2 vc_responsive">  <noscript> <iframe src="https://www.googletagmanager.com/ns.html?id=GTM-KNPGWSZ" height="0" width="0" style="display:none;visibility:hidden"></iframe> </noscript>  <div id="ts-home"></div> <div class="main-holder"> <div id="page" class="hfeed site"> <header id="masthead" class=" ts-header-style-infostack themestek-main-menu-total-5"> <div class="ts-header-block ts-mmenu-active-color-custom ts-dmenu-active-color-skin ts-dmenu-sep-grey"> <div id="site-header" class="site-header ts-bgcolor-transparent ts-sticky-bgcolor-white ts-mmmenu-override-yes ts-above-content-yes"> <div class="site-header-main ts-table"> <div class="ts-header-top-wrapper container"> <div class="site-branding"> <div class="headerlogo themestek-logotype-image ts-stickylogo-no"><span class="site-title"><span class="logo-link-text">Lexaria Bioscience - </span><a class="home-link" href="https://lexariabioscience.com/" title="Lexaria Bioscience" rel="home"><span class="ts-sc-logo ts-sc-logo-type-image"><img class="themestek-logo-img standardlogo" alt="Lexaria Bioscience" src=" http://lexariabioscience.com/wp-content/uploads/2022/03/Lexaria_Bioscience_Logo_Dark_WEB.png"></span></a></span><h2 class="site-description"></h2></div> </div> <div class="ts-infostack-right-content"> <div class="info-widget"> <div class="info-widget-inner"> </div> </div> <div class="info-widget"> <div class="info-widget-inner"> </div> </div> <div class="info-widget"> <div class="info-widget-inner"> NASDAQ:LEXX; NASDAQ WARRANT:LEXXW </div> </div> </div> </div> <div id="ts-stickable-header-w" class="ts-stickable-header-w ts-bgcolor-transparent" style="height:60px"> <div id="site-header-menu" class="site-header-menu container"> <div class="site-header-menu-inner ts-stickable-header ts-header-menu-bg-color-skincolor ts-bgcolor-skincolor ts-sticky-bgcolor-darkgrey"> <div class="site-header-menu-middle ts-header-menu-bg-color-skincolor ts-bgcolor-skincolor ts-sticky-bgcolor-darkgrey"> <div class="container "> <div> <nav id="site-navigation" class="main-navigation" aria-label="Primary Menu" data-sticky-height="90"> <button id="menu-toggle" class="menu-toggle"> <span class="ts-hide">Toggle menu</span><i class="ts-labtechco-icon-bars"></i> </button> <div class="nav-menu"><ul id="menu-main-menu" class="nav-menu"><li id="menu-item-7921" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-home menu-item-7921"><a href="https://lexariabioscience.com/">Home</a></li> <li id="menu-item-7917" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-7917"><a href="https://lexariabioscience.com/about-lexaria/">About</a> <ul class="sub-menu"> <li id="menu-item-7918" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7918"><a href="https://lexariabioscience.com/about-lexaria/#management">Management</a></li> <li id="menu-item-7948" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7948"><a href="https://lexariabioscience.com/about-lexaria/#board-of-directors">Board of Directors</a></li> <li id="menu-item-7949" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7949"><a href="https://lexariabioscience.com/about-lexaria/#advisors-and-consultants">Advisors & Consultants</a></li> </ul> </li> <li id="menu-item-7981" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-7981"><a href="https://lexariabioscience.com/technology/">Technology</a> <ul class="sub-menu"> <li id="menu-item-7987" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-7987"><a href="https://lexariabioscience.com/technology/">Overview</a></li> <li id="menu-item-7989" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7989"><a href="https://lexariabioscience.com/technology/#commercial-applications">Commercial Applications</a></li> <li id="menu-item-7982" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-7982"><a href="https://lexariabioscience.com/research/">Research</a></li> <li id="menu-item-8016" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-8016"><a href="https://lexariabioscience.com/patent-portfolio/">Patent Portfolio</a></li> </ul> </li> <li id="menu-item-8020" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-8020"><a href="https://lexariabioscience.com/licensing-opportunities/">Licensing Opportunities</a></li> <li id="menu-item-8025" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-8025"><a href="https://lexariabioscience.com/investors/">Investors</a></li> </ul></div> </nav> </div> <div class="ts-phone"> <div class="ts-header-text-area ts-header-button-w"> <div class="ts-vc_btn3-container ts-vc_btn3-inline"><a class="ts-vc_general ts-vc_btn3 ts-vc_btn3-size-md ts-vc_btn3-shape-square ts-vc_btn3-style-flat ts-vc_btn3-weight-yes ts-vc_btn3-color-skincolor" href="https://lexariabioscience.com/contact/" title="">Contact</a></div></div> </div> </div> </div> </div> </div> </div> </div> </div> <div class="ts-titlebar-wrapper ts-bg ts-bgcolor-transparent ts-titlebar-align-left ts-textcolor-white ts-bgimage-yes"> <div class="ts-titlebar-wrapper-bg-layer ts-bg-layer"></div> <div class="ts-titlebar entry-header"> <div class="ts-titlebar-inner-wrapper"> <div class="ts-titlebar-main"> <div class="container"> <div class="ts-titlebar-main-inner"> <div class="entry-title-wrapper"><div class="container"><h1 class="entry-title"> Monthly Archives: <span>March 2024</span></h1></div></div><div class="breadcrumb-wrapper"><div class="container"><div class="breadcrumb-wrapper-inner"><span><a title="Go to Lexaria Bioscience." href="https://lexariabioscience.com" class="home"><i class="fa fa-home"></i><span class="hide">Lexaria Bioscience</span></a></span> <span class="ts-bread-sep">   →  </span><span><a title="Go to Blog Large Image." href="https://lexariabioscience.com/blog-large-image/" class="post-root post post-post"><span>Blog Large Image</span></a></span><span class="ts-bread-sep">   →  </span><span><a title="Go to the 2024 archives." href="https://lexariabioscience.com/2024/" class="archive date-year"><span>2024</span></a></span><span class="ts-bread-sep">   →  </span><span><span class="archive date-month current-item">March</span></span></div></div></div> </div> </div> </div> </div> </div> </div> </div> </header> <div id="content-wrapper" class="site-content-wrapper"> <div id="content" class="site-content container"> <div id="content-inner" class="site-content-inner row multi-columns-row"> <div id="primary" class="content-area col-md-9 col-lg-9 col-xs-12"> <main id="main" class="site-main"> <article id="post-9038" class="ts-no-featured-content themestek-box-blog-classic post-9038 post type-post status-publish format-standard hentry category-press-releases" > <div class="ts-blog-classic-featured-wrapper"> <div class="ts-blog-classic-datebox-overlay"> <div class="ts-blog-classic-dbox-date">14</div> <div class="ts-blog-classic-dbox-month">Mar</div> </div> </div> <div class="ts-blog-classic-box-content ">  <div class="ts-featured-meta-wrapper ts-featured-overlay"> <div class="ts-blog-post-date"> <span class="ts-meta-line"><span class="screen-reader-text ts-hide">Date </span> <i class="ts-labtechco-icon-clock"></i> <a href="https://lexariabioscience.com/2024/03/14/lexaria-appoints-nelson-cabatuan-as-chief-financial-officer/">March 14, 2024</a></span> </div> <div class="ts-blog-post-cat ts-blog-post-cat-above-title"> <span class="ts-meta-line cat-links"><span class="screen-reader-text ts-hide">Categories </span> <i class="ts-labtechco-icon-category"></i> <a href="https://lexariabioscience.com/category/press-releases/">Press Releases</a></span> </div> <div class="themestek-box-title"><h4><a href="https://lexariabioscience.com/2024/03/14/lexaria-appoints-nelson-cabatuan-as-chief-financial-officer/">Lexaria Appoints Nelson Cabatuan as Chief Financial Officer</a></h4></div> </div>  <div class="entry-content"> <div class="themestek-box-desc-text"><div class="b2iNewsItemBodyDiv"><p><strong>KELOWNA, BC / March 14, 2024 / </strong>Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the appointment of Nelson Cabatuan, CPA, as Chief Financial Officer (CFO) effective immediately. As a member of the executive leadership team, Mr. Cabatuan will lead the Company's financial operations.</p><p>"Nelson's deep financial leadership experience will be instrumental to the execution of Lexaria's long-term growth strategy as we continue to maximize the potential use of our DehydraTECH platform for GLP-1 and other therapeutic applications with high unmet medical needs," said Chris Bunka, Chief Executive Officer of Lexaria. "On behalf of the entire Lexaria team, I'm thrilled to welcome Nelson as our CFO."</p><p>Mr. Cabatuan has over 15 years of corporate finance and operations experience within the life sciences industry, most recently serving as SVP Finance and Operations at Rain Oncology, Inc., a late-stage precision oncology biotech company. At Rain, Mr. Cabatuan built and led the company's financial organization that experienced significant growth during his tenure. Previously, Mr. Cabatuan served in various roles at Rigel Pharmaceuticals, Inc., including as Vice President Finance. At Rigel, he was a key member of the executive team that developed and launched TAVALISSE® for the treatment of chronic immune thrombocytopenia.</p><p>"Lexaria has a significant opportunity in continuing its pursuit as a global innovator in drug delivery platforms as proven by the strong potential of DehydraTECH in GLP-1 and hypertension," said Mr. Cabatuan. "I'm excited to join the team and look forward to contributing to the Company's progress in GLP-1 and other areas."</p><p><strong>About Lexaria Bioscience Corp. & DehydraTECH</strong></p><p>DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 39 patents granted and many patents pending worldwide. For more information, please visit <a href="https://pr.report/pQuN046j">www.lexariabioscience.com</a>.</p><p><strong>CAUTION REGARDING FORWARD-LOOKING STATEMENTS</strong></p><p>This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.</p><p><strong>INVESTOR CONTACT:</strong></p><p><strong>George Jurcic - Head of Investor Relations</strong><br /><a href="/cdn-cgi/l/email-protection#e28b90a28e879a83908b83808b8d91818b878c8187cc818d8f"><span class="__cf_email__" data-cfemail="89e0fbc9e5ecf1e8fbe0e8ebe0e6faeae0ece7eaeca7eae6e4">[email protected]</span></a><br />Phone: 250-765-6424, ext 202</p><p><strong>SOURCE:</strong> Lexaria Bioscience Corp.</p><img src='https://www.accesswire.com/img.ashx?id=842800' /><br><br>View the original <a href='https://www.accesswire.com/842800/lexaria-appoints-nelson-cabatuan-as-chief-financial-officer'>press release</a> on accesswire.com<br><br></div></div> <div class="themestek-blog-classic-footer-readmore"> <div class="themestek-blogbox-footer-left"><a href="https://lexariabioscience.com/2024/03/14/lexaria-appoints-nelson-cabatuan-as-chief-financial-officer/">Read More</a></div> </div> <div class="ts-footer-meta-wrapper"> <span class="ts-footer-meta-line-w ts-footer-meta-line-comments"> <a href="https://lexariabioscience.com/2024/03/14/lexaria-appoints-nelson-cabatuan-as-chief-financial-officer/"> <i class="ts-labtechco-icon-comment-1"></i> <span class="comments"> 0 Comments </span> </a> </span> <span class="ts-footer-meta-line-w ts-footer-meta-line-author"> <span class="author vcard"> <span class="screen-reader-text ts-hide">Author </span> <a class="url fn n" href="https://lexariabioscience.com/author/mmcdonald/"><i class="ts-labtechco-icon-user"></i> mmcdonald</a> </span> </span> </div> </div> </div> </article> <article id="post-9039" class="ts-no-featured-content themestek-box-blog-classic post-9039 post type-post status-publish format-standard hentry category-press-releases" > <div class="ts-blog-classic-featured-wrapper"> <div class="ts-blog-classic-datebox-overlay"> <div class="ts-blog-classic-dbox-date">07</div> <div class="ts-blog-classic-dbox-month">Mar</div> </div> </div> <div class="ts-blog-classic-box-content ">  <div class="ts-featured-meta-wrapper ts-featured-overlay"> <div class="ts-blog-post-date"> <span class="ts-meta-line"><span class="screen-reader-text ts-hide">Date </span> <i class="ts-labtechco-icon-clock"></i> <a href="https://lexariabioscience.com/2024/03/07/lexaria-awards-contract-for-next-glp-1-human-pilot-study/">March 7, 2024</a></span> </div> <div class="ts-blog-post-cat ts-blog-post-cat-above-title"> <span class="ts-meta-line cat-links"><span class="screen-reader-text ts-hide">Categories </span> <i class="ts-labtechco-icon-category"></i> <a href="https://lexariabioscience.com/category/press-releases/">Press Releases</a></span> </div> <div class="themestek-box-title"><h4><a href="https://lexariabioscience.com/2024/03/07/lexaria-awards-contract-for-next-glp-1-human-pilot-study/">Lexaria Awards Contract For Next GLP-1 Human Pilot Study</a></h4></div> </div>  <div class="entry-content"> <div class="themestek-box-desc-text"><div class="b2iNewsItemBodyDiv"><ul><li><i><strong>First-ever dissolvable DehydraTECH-GLP-1 oral dose formulation to be tested</strong></i></li><li><i><strong>Rybelsus</strong></i><sup>®</sup><i><strong> semaglutide will act as the positive control</strong></i></li></ul><p><strong>KELOWNA, BC / March 7, 2024 / </strong>Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has hired a contract research organization ("<strong>CRO</strong>") to perform the Company's second DehydraTECH-powered glucagon-like peptide 1 ("GLP-1") human pilot study #2 (the "<strong>Study</strong>").</p><p>The Study will be a randomized, crossover, placebo-controlled investigation that will compare three dose formulations each at a 7 mg semaglutide dose:</p><ul><li>a positive control Rybelsus<sup>®</sup> swallowed tablet;</li><li>DehydraTECH-semaglutide swallowed capsules; and,</li><li>for the first time ever, an in-mouth dissolvable DehydraTECH-semaglutide oral tablet.</li></ul><p>Semaglutide swallowed into the stomach/intestine absorbs into the bloodstream at an exceptionally low rate typically at <a href="https://pr.report/tyB61ZJo">less than 1%, </a>when it does not use any absorption technology because, in part, the acidic environment of the stomach is known to seriously degrade GLP-1 drugs.</p><p>"DehydraTECH has previously shown an ability to improve delivery of certain drugs destined for the bloodstream, through the buccal/sublingual tissues of the mouth and throat," said Chris Bunka, CEO of Lexaria Bioscience Corp. "If this new Study is successful in demonstrating efficacy and safety, the potential for a new era in GLP-1 delivery without the need for painful injections or stomach-upsetting tablets, could be within reach."</p><p>Manufacturing of the test articles for this Study is anticipated to be completed within 30 days. Independent Review Board approval is required before the Study can commence, and the Company will provide our next update when dosing has begun.</p><p><strong>CORRECTION</strong></p><p>In Lexaria's <a href="https://pr.report/nOCiljX9">press release of March 4</a>, we described an upcoming animal study as having an 8-week duration. That was a typographical error: the correct animal study duration is 12-weeks.</p><p><strong>About the Study</strong></p><p>Many design characteristics of the Study will be fundamentally the same as in Lexaria's initial <a href="https://pr.report/ks6UJizf">human pilot study</a>. The DehydraTECH-semaglutide test articles will be compound formulated using crushed Rybelsus®tablets strictly for research purposes. The Study is designed to measure tolerability and side effects, blood levels of semaglutide, and blood glucose levels. Blood samples will be taken multiple times during the first 10 hours post dosing; a final blood draw will be taken 24 hours after dosing; and, a standardized meal will be fed to the test subjects at a point in time after dosing. Eight healthy subjects are expected to be dosed with each test article following a cross over study design across three study visits.</p><p><strong>About Semaglutide</strong></p><p>Rybelsus<sup>®</sup> (semaglutide) is <a href="https://pr.report/yjTIaORr">the only GLP-1 drug approved by the FDA</a> <i>for oral dosing</i> to treat diabetes and weight loss. The FDA has also approved semaglutide marketed as Ozempic<sup>®</sup> and Wegovy<sup>®</sup>, <i>administered by injection</i>, to treat diabetes and weight loss. All three of these drugs are owned and manufactured by Novo Nordisk<sup>®</sup>.</p><p><strong>About Lexaria Bioscience Corp. & DehydraTECH</strong></p><p>DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 39 patents granted and many patents pending worldwide. For more information, please visit <a href="https://pr.report/ScZ5Bv6d">www.lexariabioscience.com</a>.</p><p><strong>CAUTION REGARDING FORWARD-LOOKING STATEMENTS</strong></p><p>This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.</p><p><strong>INVESTOR CONTACT:</strong></p><p><strong>George Jurcic - Head of Investor Relations</strong><br /><a href="/cdn-cgi/l/email-protection#84edf6c4e8e1fce5f6ede5e6edebf7e7ede1eae7e1aae7ebe9"><span class="__cf_email__" data-cfemail="056c774569607d64776c64676c6a76666c606b66602b666a68">[email protected]</span></a><br />Phone: 250-765-6424, ext 202</p><p><strong>SOURCE:</strong> Lexaria Bioscience Corp.</p><img src='https://www.accesswire.com/img.ashx?id=840107' /><br><br>View the original <a href='https://www.accesswire.com/840107/lexaria-awards-contract-for-next-glp-1-human-pilot-study'>press release</a> on accesswire.com<br><br></div></div> <div class="themestek-blog-classic-footer-readmore"> <div class="themestek-blogbox-footer-left"><a href="https://lexariabioscience.com/2024/03/07/lexaria-awards-contract-for-next-glp-1-human-pilot-study/">Read More</a></div> </div> <div class="ts-footer-meta-wrapper"> <span class="ts-footer-meta-line-w ts-footer-meta-line-comments"> <a href="https://lexariabioscience.com/2024/03/07/lexaria-awards-contract-for-next-glp-1-human-pilot-study/"> <i class="ts-labtechco-icon-comment-1"></i> <span class="comments"> 0 Comments </span> </a> </span> <span class="ts-footer-meta-line-w ts-footer-meta-line-author"> <span class="author vcard"> <span class="screen-reader-text ts-hide">Author </span> <a class="url fn n" href="https://lexariabioscience.com/author/mmcdonald/"><i class="ts-labtechco-icon-user"></i> mmcdonald</a> </span> </span> </div> </div> </div> </article> <article id="post-9040" class="ts-no-featured-content themestek-box-blog-classic post-9040 post type-post status-publish format-standard hentry category-press-releases" > <div class="ts-blog-classic-featured-wrapper"> <div class="ts-blog-classic-datebox-overlay"> <div class="ts-blog-classic-dbox-date">05</div> <div class="ts-blog-classic-dbox-month">Mar</div> </div> </div> <div class="ts-blog-classic-box-content ">  <div class="ts-featured-meta-wrapper ts-featured-overlay"> <div class="ts-blog-post-date"> <span class="ts-meta-line"><span class="screen-reader-text ts-hide">Date </span> <i class="ts-labtechco-icon-clock"></i> <a href="https://lexariabioscience.com/2024/03/05/lexaria-to-begin-diabetes-and-weight-loss-animal-study-weight-a24-1/">March 5, 2024</a></span> </div> <div class="ts-blog-post-cat ts-blog-post-cat-above-title"> <span class="ts-meta-line cat-links"><span class="screen-reader-text ts-hide">Categories </span> <i class="ts-labtechco-icon-category"></i> <a href="https://lexariabioscience.com/category/press-releases/">Press Releases</a></span> </div> <div class="themestek-box-title"><h4><a href="https://lexariabioscience.com/2024/03/05/lexaria-to-begin-diabetes-and-weight-loss-animal-study-weight-a24-1/">Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1</a></h4></div> </div>  <div class="entry-content"> <div class="themestek-box-desc-text"><div class="b2iNewsItemBodyDiv"><ul><li><i><strong>Multiple DehydraTECH-GLP-1 and DehydraTECH-CBD formulations to be tested</strong></i></li><li><i><strong>Chronic dosing over a 12-week treatment period</strong></i></li><li><i><strong>Will assess weight loss and blood glucose level control</strong></i></li><li><i><strong>Efficacy through possible brain absorption delivery enhancement to be assessed</strong></i></li></ul><p><strong>KELOWNA, BC / March 5, 2024 / </strong>Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces details of an 8-week animal study <strong>WEIGHT-A24-1</strong> (the "<strong>Study</strong>") to examine diabetes and weight loss effects of DehydraTECH-processed glucagon-like peptide 1 ("GLP-1") drugs and DehydraTECH-processed cannabidiol, alone and in combination.</p><p>The contract for the Study has been awarded to a third-party, Health Canada-licensed Canadian research laboratory. Manufacturing of the compositions for the first 8 of the 12 arms of the Study has already been completed, and those arms will commence as soon as the testing laboratory is able to do so, expected to begin within 45 days.</p><p>Detailed information of the 12 Study arms is as noted:</p><ul><li>Group 1: DehydraTECH-CBD (composition "A")</li><li>Group 2: DehydraTECH-CBD (composition "B")</li><li>Group 3: DehydraTECH-CBD (composition "C")</li><li>Group 4: DehydraTECH-CBD (composition "D")</li><li>Group 5: DehydraTECH-GLP-1 (re-formulated Rybelsus® "E")</li><li>Group 6: DehydraTECH-GLP-1 (re-formulated Rybelsus® "F")</li><li>Group 7: DehydraTECH-GLP-1 (pure semaglutide "G")</li><li>Group 8: DehydraTECH-GLP-1 (pure liraglutide "H")</li><li>Group 9: Combination of one of E, F, or G and one of A, B, C, or D (TBD)</li><li>Group 10: Combination of H and one of A, B, C, or D (TBD)</li><li>Group 11: Vehicle (placebo) arm</li><li>Group 12: Positive control arm</li></ul><p>Each arm of the Study will be dosed for an 8-week period following an acclimation period. During the Study, over 1,500 blood plasma samples will be collected from the total rat population of 72 animals for purposes of detailed pharmacokinetic drug delivery analyses. Body weight and blood glucose readings will be taken prior to Study start and at regular intervals during and at conclusion of the dosing period. Upon completion of the Study, brain tissue will be analysed to help determine whether DehydraTECH processing results in higher brain absorption than non-DehydraTECH arms, as Lexaria has evidenced numerous times in previous similar animal studies. <a href="https://pr.report/z1pgJqTY">LC-MS/MS</a> and other techniques will be used to analyse samples. Also, the Study will allow examination of DehydraTECH-processed semaglutide with and <i>without</i> the salcaprozate sodium "SNAC" technology currently found within Rybelsus® tablets. We will be collecting and reporting interim results prior to the end of the Study.</p><p>Study arms 9 and 10 will have a later start-date due to some information outputs required from the other Study arms before they and study arms 11 and 12 can commence. The Company will provide an update when animal dosing has begun.</p><p>In previous animal research with two other molecules, including cannabidiol, Lexaria demonstrated through brain tissue examination that DehydraTECH processing can enable higher levels of drug delivery across the blood-brain-barrier and directly into brain tissue. It is unknown, today, whether DehydraTECH processing can deliver higher quantities of GLP-1 drugs into brain tissue, and Study WEIGHT-A24-1 is designed to answer that question in animals.</p><p><a href="https://pr.report/6XUWcxIv">Recent research</a> has indicated "<i>that a small peptide GLP-1R agonist penetrates the brain and activates a subset of GLP-1R-expressing neurons in the arcuate nucleus to produce weight loss</i>." Lexaria believes that, if it can evidence that DehydraTECH processing of GLP-1 drugs can enable greater penetration into brain tissue, then this may help to explain how the GLP-1 drug(s) powered by DehydraTECH may be more effective at enhancing beneficial outcomes such as weight loss and blood sugar control. In turn, this could also potentially allow for lower dosing and a concomitant reduction in adverse side effects.</p><p><strong>About Lexaria Bioscience Corp. & DehydraTECH</strong></p><p>DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 39 patents granted and many patents pending worldwide. For more information, please visit <a href="https://pr.report/iNCaJVhd">www.lexariabioscience.com</a>.</p><p><strong>CAUTION REGARDING FORWARD-LOOKING STATEMENTS</strong></p><p>This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.</p><p><strong>INVESTOR CONTACT:</strong></p><p><strong>George Jurcic - Head of Investor Relations</strong><br /><a href="/cdn-cgi/l/email-protection#0f667d4f636a776e7d666e6d66607c6c666a616c6a216c6062"><span class="__cf_email__" data-cfemail="056c774569607d64776c64676c6a76666c606b66602b666a68">[email protected]</span></a><br />Phone: 250-765-6424, ext 202</p><p><strong>SOURCE:</strong> Lexaria Bioscience Corp.</p><img src='https://www.accesswire.com/img.ashx?id=839263' /><br><br>View the original <a href='https://www.accesswire.com/839263/lexaria-to-begin-diabetes-and-weight-loss-animal-study-weight-a24-1'>press release</a> on accesswire.com<br><br></div></div> <div class="themestek-blog-classic-footer-readmore"> <div class="themestek-blogbox-footer-left"><a href="https://lexariabioscience.com/2024/03/05/lexaria-to-begin-diabetes-and-weight-loss-animal-study-weight-a24-1/">Read More</a></div> </div> <div class="ts-footer-meta-wrapper"> <span class="ts-footer-meta-line-w ts-footer-meta-line-comments"> <a href="https://lexariabioscience.com/2024/03/05/lexaria-to-begin-diabetes-and-weight-loss-animal-study-weight-a24-1/"> <i class="ts-labtechco-icon-comment-1"></i> <span class="comments"> 0 Comments </span> </a> </span> <span class="ts-footer-meta-line-w ts-footer-meta-line-author"> <span class="author vcard"> <span class="screen-reader-text ts-hide">Author </span> <a class="url fn n" href="https://lexariabioscience.com/author/mmcdonald/"><i class="ts-labtechco-icon-user"></i> mmcdonald</a> </span> </span> </div> </div> </div> </article> <article id="post-9041" class="ts-no-featured-content themestek-box-blog-classic post-9041 post type-post status-publish format-standard hentry category-press-releases" > <div class="ts-blog-classic-featured-wrapper"> <div class="ts-blog-classic-datebox-overlay"> <div class="ts-blog-classic-dbox-date">04</div> <div class="ts-blog-classic-dbox-month">Mar</div> </div> </div> <div class="ts-blog-classic-box-content ">  <div class="ts-featured-meta-wrapper ts-featured-overlay"> <div class="ts-blog-post-date"> <span class="ts-meta-line"><span class="screen-reader-text ts-hide">Date </span> <i class="ts-labtechco-icon-clock"></i> <a href="https://lexariabioscience.com/2024/03/04/7-weight-loss-in-animals-supports-lexarias-next-8-week-animal-study/">March 4, 2024</a></span> </div> <div class="ts-blog-post-cat ts-blog-post-cat-above-title"> <span class="ts-meta-line cat-links"><span class="screen-reader-text ts-hide">Categories </span> <i class="ts-labtechco-icon-category"></i> <a href="https://lexariabioscience.com/category/press-releases/">Press Releases</a></span> </div> <div class="themestek-box-title"><h4><a href="https://lexariabioscience.com/2024/03/04/7-weight-loss-in-animals-supports-lexarias-next-8-week-animal-study/">7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal Study</a></h4></div> </div>  <div class="entry-content"> <div class="themestek-box-desc-text"><div class="b2iNewsItemBodyDiv"><p><strong>KELOWNA, BC / March 4, 2024 /</strong> Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, informs that its wholly-owned and patented DehydraTECH-CBD formulation, when administered to rodents in an 8-week study (DIAB-A22-1), resulted in <a href="https://pr.report/dRsr6hTI">weight loss of 7%</a> and a reduction of <a href="https://pr.report/gZtcGWhr">19.9% (p<0.05) in blood glucose</a>. Lexaria has now signed contracts to begin animal study WEIGHT-A24-1; (the "<strong>Study</strong>"), which will be a large, multi-week animal study that will substantially progress its further DehydraTECH-GLP-1 and DehydraTECH-CBD weight loss investigations.</p><p>Lexaria also <a href="https://pr.report/y3VAXw9H">recently published results</a> in a human study, wherein a single 7 mg semaglutide dose from Rybelsus® processed with DehydraTECH and administered to humans, was absorbed at a significantly higher level than without DehydraTECH processing; and also managed blood glucose levels more effectively without any blood glucose spiking after eating.</p><p>Together, these discoveries strongly support additional investigations, including:</p><ul><li>determining whether daily dosing of DehydraTECH-GLP-1 might result in sustained higher concentrations of GLP-1 in blood over an extended treatment duration than without DehydraTECH processing; and whether such a higher blood concentration might result in greater weight loss over time, and</li><li>determining whether DehydraTECH-CBD, specially formulated for diabetes control and weight loss, alone and/<i>or in conjunction with DehydraTECH-GLP-1</i>, might also result in greater weight loss and/or blood glucose control over time.</li></ul><p>Manufacturing of the test articles for 8 of the 12 arms of the new animal Study has already been completed, and dosing in those arms will commence as soon as the third-party laboratory is able to do so, expected to begin within 45 days. Four different DehydraTECH-CBD compositions will be tested, as well as 4 different DehydraTECH-GLP-1 compositions (comprised of 3 different DehydraTECH-semaglatide formulas and a single, first ever DehydraTECH-liraglutide composition). The comprehensive Study will also test 1 DehydraTECH-CBD composition combined with DehydraTECH-semaglutide; and 1 DehydraTECH-CBD composition combined with the DehydraTECH-liraglutide composition.</p><p>More detailed Study information will be released soon about study WEIGHT-A24-1 in separate news.</p><p><strong>THE MARKET OPPORTUNITY</strong></p><p>Rybelsus® (semaglutide) is <a href="https://pr.report/3ILbG27a">the only GLP-1 drug approved by the FDA</a> <i>for oral dosing</i> to treat diabetes and weight loss. The FDA has also approved semaglutide marketed as Ozempic® and Wegovy®, <i>administered by injection</i>, to treat diabetes and weight loss. All three of these drugs are owned and manufactured by Novo Nordisk.</p><p>GLP-1 drugs have recently been approved by the FDA for type two diabetes and weight loss management. Weight loss of <a href="https://pr.report/qpQCfad8">between 10 pounds to 33 pounds</a>, or more, has been widely reported. One 68-week study of 667 people reported an <a href="https://pr.report/Vfdu5J2Q">average loss of 15% of body weight</a>.</p><p>Because GLP-1 drugs have experienced FDA approvals as recently as 2021 and 2022, and because the health benefits of this drug class are still being discovered and understood, the potential market size is unknown. Published reports are widely estimating $100 billion in sales per year, by 2030. At least one analyst from Guggenheim Partners published a note on September 12, 2023 in which he explained how "the total addressable market for these so-called incretin drugs <a href="https://pr.report/S-IUukjt">could balloon to $150 billion to $200 billion</a>."</p><p>Diabetes is a disease whereby the body does not produce sufficient insulin, leading to higher than normal levels of sugars in the blood. Risks of <a href="https://pr.report/pnl5O2Yo">kidney disease, vision loss, heart and cardiovascular disease</a> and more are greatly enhanced by individuals with diabetes. Because diabetes is often closely connected to obesity, it is a chronic and growing problem around much of the world.</p><p>People with type-2 diabetes can often control the disease through lifestyle changes and/or taking certain diabetes medications, whereas those with type-1 diabetes are required to add insulin to their body through syringes, insulin pumps, or other similar devices. Thus, the treatment of diabetes includes devices, drugs, and lifestyle alteration. The global diabetes devices market is <a href="https://pr.report/tn3aJ9ZI">estimated at $26.7 billion in 2021</a>. The global diabetes drug market is <a href="https://pr.report/DRayOI6Q">estimated at $63.1 billion in 2021</a>. Due to the pain and unpleasantness of injections, many diabetes sufferers prefer to treat their condition with drugs rather than devices, if they have the choice. More than 1.9 billion people were overweight in 2016, and due to the growth in obesity, which has <a href="https://pr.report/1FC82sry">nearly tripled from 1975 to 2016</a>, the number of people experiencing diabetes continues to grow.</p><p><strong>About Lexaria Bioscience Corp. & DehydraTECH</strong></p><p>DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 39 patents granted and many patents pending worldwide. For more information, please visit <a href="https://pr.report/cvuRyprz">www.lexariabioscience.com</a>.</p><p><strong>CAUTION REGARDING FORWARD-LOOKING STATEMENTS</strong></p><p>This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.</p><p><strong>INVESTOR CONTACT:</strong></p><p><strong>George Jurcic - Head of Investor Relations</strong><br /><a href="/cdn-cgi/l/email-protection#a9c0dbe9c5ccd1c8dbc0c8cbc0c6dacac0ccc7cacc87cac6c4"><span class="__cf_email__" data-cfemail="771e05371b120f16051e16151e1804141e121914125914181a">[email protected]</span></a><br />Phone: 250-765-6424, ext 202</p><p><strong>SOURCE:</strong> Lexaria Bioscience Corp.</p><img src='https://www.accesswire.com/img.ashx?id=838729' /><br><br>View the original <a href='https://www.accesswire.com/838729/7-weight-loss-in-animals-supports-lexarias-next-8-week-animal-study'>press release</a> on accesswire.com<br><br></div></div> <div class="themestek-blog-classic-footer-readmore"> <div class="themestek-blogbox-footer-left"><a href="https://lexariabioscience.com/2024/03/04/7-weight-loss-in-animals-supports-lexarias-next-8-week-animal-study/">Read More</a></div> </div> <div class="ts-footer-meta-wrapper"> <span class="ts-footer-meta-line-w ts-footer-meta-line-comments"> <a href="https://lexariabioscience.com/2024/03/04/7-weight-loss-in-animals-supports-lexarias-next-8-week-animal-study/"> <i class="ts-labtechco-icon-comment-1"></i> <span class="comments"> 0 Comments </span> </a> </span> <span class="ts-footer-meta-line-w ts-footer-meta-line-author"> <span class="author vcard"> <span class="screen-reader-text ts-hide">Author </span> <a class="url fn n" href="https://lexariabioscience.com/author/mmcdonald/"><i class="ts-labtechco-icon-user"></i> mmcdonald</a> </span> </span> </div> </div> </div> </article> <article id="post-9042" class="ts-no-featured-content themestek-box-blog-classic post-9042 post type-post status-publish format-standard hentry category-press-releases" > <div class="ts-blog-classic-featured-wrapper"> <div class="ts-blog-classic-datebox-overlay"> <div class="ts-blog-classic-dbox-date">01</div> <div class="ts-blog-classic-dbox-month">Mar</div> </div> </div> <div class="ts-blog-classic-box-content ">  <div class="ts-featured-meta-wrapper ts-featured-overlay"> <div class="ts-blog-post-date"> <span class="ts-meta-line"><span class="screen-reader-text ts-hide">Date </span> <i class="ts-labtechco-icon-clock"></i> <a href="https://lexariabioscience.com/2024/03/01/lexaria-announces-fda-clearance-for-its-planned-u-s-phase-1b-hypertension-clinical-trial/">March 1, 2024</a></span> </div> <div class="ts-blog-post-cat ts-blog-post-cat-above-title"> <span class="ts-meta-line cat-links"><span class="screen-reader-text ts-hide">Categories </span> <i class="ts-labtechco-icon-category"></i> <a href="https://lexariabioscience.com/category/press-releases/">Press Releases</a></span> </div> <div class="themestek-box-title"><h4><a href="https://lexariabioscience.com/2024/03/01/lexaria-announces-fda-clearance-for-its-planned-u-s-phase-1b-hypertension-clinical-trial/">Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial</a></h4></div> </div>  <div class="entry-content"> <div class="themestek-box-desc-text"><div class="b2iNewsItemBodyDiv"><p><strong>KELOWNA, BC / March 1, 2024 /</strong> Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that the U.S. Food and Drug Administration ("FDA") has confirmed effectiveness as of February 28, 2024 of the Company's investigational new drug ("IND") application thereby cleared for Lexaria to conduct its planned U.S. Phase 1b hypertension clinical trial HYPER-H23-1 utilizing DehydraTECH-CBD.</p><p>"This is a significant milestone achievement for Lexaria demonstrating, for the first time, that its DehydraTECH technology meets the FDA's high level of regulatory scrutiny sufficient to formally commence U.S. registrational clinical testing towards possible future pharmaceutical commercialization," said John Docherty, president of Lexaria. "We look forward to commencing this important clinical trial and building upon the wealth of early-stage clinical data we have gathered and presented to the FDA to-date demonstrating the safety, efficacy and novel mechanistic performance of DehydraTECH-CBD in hypertensive patients."</p><p>Lexaria is pleased to have complied with the FDA's rules and procedures for clearance to perform this important registrational trial. The Company will further announce when it is ready to begin the study, subject to certain conditions including raising sufficient funding.</p><p><strong>Background and Medical/Market Rationale</strong></p><p>From 2018 through 2022, Lexaria has previously conducted five human clinical studies of DehydraTECH-CBD in an aggregate total of 134 healthy normal and hypertensive volunteers, without recording a single serious adverse event (the "Studies"). The Studies evidenced significant reductions in resting blood pressure over both acute and multi-week dosing regimens, and also produced zero serious adverse events; suggesting that DehydraTECH-CBD has the potential to have pronounced clinical benefits relative to available anti-hypertensive therapeutics.</p><p>Lexaria is aware of only a handful of <a href="https://pr.report/Kk9erzGE">other published research studies</a>, mostly in young, healthy and normotensive volunteers, that have investigated whether a sustained decrease in resting blood pressure is possible following multiple weeks of oral CBD dosing; none of which have been successful in achieving this. DehydraTECH-CBD is currently unique in its evidenced superior power to reduce blood pressure over other oral CBD formulations.</p><p>Findings from Lexaria's study HYPER-H21-4 <a href="https://pr.report/fuoa2Ry3">demonstrated a potentially novel mechanism of action</a> of DehydraTECH-CBD in reducing blood pressure which may be explained, at least in part, by its interaction with the human sympatho-chromaffin system via catestatin modulation as detailed in the <a href="https://pr.report/aND8kVW7">peer-reviewed and published</a> journal, "<i>Biomedicine and Pharmacotherapy</i>". This is significant because the FDA has previously communicated <a href="https://pr.report/DGgrCMOv">clear guidelines for sponsors</a> who seek to develop new anti-hypertensive drugs, specifically defining the need for medications that offer novel and complementary modes of action.</p><p><strong>About Planned Clinical Trial HYPER-H23-1</strong></p><p>Clinical trial HYPER-H23-1 is entitled '<i>A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DehydraTECH-CBD in Subjects with Stage 1 or Stage 2 Hypertension'</i>. The primary objective of the trial will be to evaluate safety and tolerability in hypertensive patients, and secondary objectives will include efficacy evaluation in reducing blood pressure together with detailed pharmacokinetic testing.</p><p><strong>About Lexaria Bioscience Corp. & DehydraTECH</strong></p><p>DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 39 patents granted and many patents pending worldwide. For more information, please visit <a href="https://pr.report/caU0G4TV">www.lexariabioscience.com</a>.</p><p><strong>CAUTION REGARDING FORWARD-LOOKING STATEMENTS</strong></p><p>This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, the intended use of proceeds from the offering, and the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.</p><p><strong>INVESTOR CONTACT:</strong></p><p><strong>George Jurcic - Head of Investor Relations</strong><br /><a href="/cdn-cgi/l/email-protection#741d063418110c15061d15161d1b07171d111a17115a171b19"><span class="__cf_email__" data-cfemail="345d467458514c55465d55565d5b47575d515a57511a575b59">[email protected]</span></a><br />Phone: 250-765-6424, ext 202</p><p><strong>SOURCE: </strong>Lexaria Bioscience Corp.</p><img src='https://www.accesswire.com/img.ashx?id=838046' /><br><br>View the original <a href='https://www.accesswire.com/838046/lexaria-announces-fda-clearance-for-its-planned-us-phase-1b-hypertension-clinical-trial'>press release</a> on accesswire.com<br><br></div></div> <div class="themestek-blog-classic-footer-readmore"> <div class="themestek-blogbox-footer-left"><a href="https://lexariabioscience.com/2024/03/01/lexaria-announces-fda-clearance-for-its-planned-u-s-phase-1b-hypertension-clinical-trial/">Read More</a></div> </div> <div class="ts-footer-meta-wrapper"> <span class="ts-footer-meta-line-w ts-footer-meta-line-comments"> <a href="https://lexariabioscience.com/2024/03/01/lexaria-announces-fda-clearance-for-its-planned-u-s-phase-1b-hypertension-clinical-trial/"> <i class="ts-labtechco-icon-comment-1"></i> <span class="comments"> 0 Comments </span> </a> </span> <span class="ts-footer-meta-line-w ts-footer-meta-line-author"> <span class="author vcard"> <span class="screen-reader-text ts-hide">Author </span> <a class="url fn n" href="https://lexariabioscience.com/author/mmcdonald/"><i class="ts-labtechco-icon-user"></i> mmcdonald</a> </span> </span> </div> </div> </div> </article> <div class="clearfix"></div> </main> </div> <aside id="sidebar-right" class="widget-area col-md-3 col-lg-3 col-xs-12 sidebar"> <aside id="search-2" class="widget-even widget-6 widget widget_search"><form role="search" method="get" class="search-form" action="https://lexariabioscience.com/"> <label> <span class="screen-reader-text">Search for:</span> <input type="search" class="search-field" placeholder="Search …" value="" name="s" /> </label> <input type="submit" class="search-submit" value="Search" /> </form></aside><aside id="categories-2" class="widget-odd widget-7 widget widget_categories"><h3 class="widget-title">Categories</h3> <ul> <li class="cat-item cat-item-2"><a href="https://lexariabioscience.com/category/chemistry-laboratories/">Chemistry</a> <span>1</span> </li> <li class="cat-item cat-item-3"><a href="https://lexariabioscience.com/category/forensic-science/">Forensic science</a> <span>3</span> </li> <li class="cat-item cat-item-4"><a href="https://lexariabioscience.com/category/gemological-laboratories/">Gemological</a> <span>3</span> </li> <li class="cat-item cat-item-37"><a href="https://lexariabioscience.com/category/press-releases/">Press Releases</a> <span>157</span> </li> <li class="cat-item cat-item-5"><a href="https://lexariabioscience.com/category/scientific-laboratory/">Scientific</a> <span>3</span> </li> <li class="cat-item cat-item-1"><a href="https://lexariabioscience.com/category/uncategorized/">Uncategorized</a> <span>1</span> </li> </ul> </aside> <aside id="themestek-recent-posts-2" class="widget-even widget-8 widget themestek_widget_recent_entries"> <h3 class="widget-title">Recent Posts</h3> <ul class="ts-recent-post-list"> <li class="ts-recent-post-list-li"><a href="https://lexariabioscience.com/2024/11/20/all-study-groups-using-dehydratech-processing-outperform-rybelsus-in-body-weight-control-in-lexarias-12-week-glp-1-diabetes-animal-study/">ALL Study Groups using DehydraTECH Processing Outperform Rybelsus® in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study</a><span class="post-date">November 20, 2024</span></li><li class="ts-recent-post-list-li"><a href="https://lexariabioscience.com/2024/11/14/lexaria-signs-contract-for-new-dehydratech-glp-1-biodistribution-study/">Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study</a><span class="post-date">November 14, 2024</span></li><li class="ts-recent-post-list-li"><a href="https://lexariabioscience.com/2024/11/13/ethics-board-approval-granted-for-lexarias-12-week-phase-1b-dehydratech-glp-1-study-in-diabetes-and-weight-loss/">Ethics Board Approval Granted for Lexaria’s 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss</a><span class="post-date">November 13, 2024</span></li><li class="ts-recent-post-list-li"><a href="https://lexariabioscience.com/2024/11/07/lexaria-updates-fast-moving-glp-1-arms-race-developments/">Lexaria Updates Fast-Moving GLP-1 ‘Arm’s Race’ Developments</a><span class="post-date">November 7, 2024</span></li><li class="ts-recent-post-list-li"><a href="https://lexariabioscience.com/2024/10/24/positive-partial-12-week-blood-sugar-results-from-lexarias-glp-1-diabetes-animal-study/">Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study</a><span class="post-date">October 24, 2024</span></li> </ul> </aside> <aside id="tag_cloud-2" class="widget-odd widget-9 widget widget_tag_cloud"><h3 class="widget-title">Tags</h3><div class="tagcloud"><a href="https://lexariabioscience.com/tag/biochemistry-research/" class="tag-cloud-link tag-link-6 tag-link-position-1" style="font-size: 22pt;" aria-label="Biochemistry research (3 items)">Biochemistry research</a> <a href="https://lexariabioscience.com/tag/chemistry/" class="tag-cloud-link tag-link-7 tag-link-position-2" style="font-size: 22pt;" aria-label="Chemistry (3 items)">Chemistry</a> <a href="https://lexariabioscience.com/tag/equipment/" class="tag-cloud-link tag-link-8 tag-link-position-3" style="font-size: 8pt;" aria-label="equipment‎ (2 items)">equipment‎</a> <a href="https://lexariabioscience.com/tag/medical/" class="tag-cloud-link tag-link-9 tag-link-position-4" style="font-size: 8pt;" aria-label="Medical (2 items)">Medical</a> <a href="https://lexariabioscience.com/tag/physics/" class="tag-cloud-link tag-link-10 tag-link-position-5" style="font-size: 22pt;" aria-label="Physics (3 items)">Physics</a> <a href="https://lexariabioscience.com/tag/scientific-research/" class="tag-cloud-link tag-link-11 tag-link-position-6" style="font-size: 22pt;" aria-label="scientific research (3 items)">scientific research</a></div> </aside><aside id="archives-3" class="widget-even widget-10 widget widget_archive"><h3 class="widget-title">Archives</h3> <ul> <li><a href='https://lexariabioscience.com/2024/11/'>November 2024</a></li> <li><a href='https://lexariabioscience.com/2024/10/'>October 2024</a></li> <li><a href='https://lexariabioscience.com/2024/09/'>September 2024</a></li> <li><a href='https://lexariabioscience.com/2024/08/'>August 2024</a></li> <li><a href='https://lexariabioscience.com/2024/07/'>July 2024</a></li> <li><a href='https://lexariabioscience.com/2024/06/'>June 2024</a></li> <li><a href='https://lexariabioscience.com/2024/05/'>May 2024</a></li> <li><a href='https://lexariabioscience.com/2024/04/'>April 2024</a></li> <li><a href='https://lexariabioscience.com/2024/03/' aria-current="page">March 2024</a></li> <li><a href='https://lexariabioscience.com/2024/02/'>February 2024</a></li> <li><a href='https://lexariabioscience.com/2024/01/'>January 2024</a></li> <li><a href='https://lexariabioscience.com/2023/12/'>December 2023</a></li> <li><a href='https://lexariabioscience.com/2023/11/'>November 2023</a></li> <li><a href='https://lexariabioscience.com/2023/10/'>October 2023</a></li> <li><a href='https://lexariabioscience.com/2023/09/'>September 2023</a></li> <li><a href='https://lexariabioscience.com/2023/08/'>August 2023</a></li> <li><a href='https://lexariabioscience.com/2023/07/'>July 2023</a></li> <li><a href='https://lexariabioscience.com/2023/06/'>June 2023</a></li> <li><a href='https://lexariabioscience.com/2023/05/'>May 2023</a></li> <li><a href='https://lexariabioscience.com/2023/04/'>April 2023</a></li> <li><a href='https://lexariabioscience.com/2023/03/'>March 2023</a></li> <li><a href='https://lexariabioscience.com/2023/02/'>February 2023</a></li> <li><a href='https://lexariabioscience.com/2023/01/'>January 2023</a></li> <li><a href='https://lexariabioscience.com/2022/12/'>December 2022</a></li> <li><a href='https://lexariabioscience.com/2022/11/'>November 2022</a></li> <li><a href='https://lexariabioscience.com/2022/10/'>October 2022</a></li> <li><a href='https://lexariabioscience.com/2022/09/'>September 2022</a></li> <li><a href='https://lexariabioscience.com/2022/08/'>August 2022</a></li> <li><a href='https://lexariabioscience.com/2022/07/'>July 2022</a></li> <li><a href='https://lexariabioscience.com/2022/06/'>June 2022</a></li> <li><a href='https://lexariabioscience.com/2022/05/'>May 2022</a></li> <li><a href='https://lexariabioscience.com/2022/04/'>April 2022</a></li> <li><a href='https://lexariabioscience.com/2022/03/'>March 2022</a></li> <li><a href='https://lexariabioscience.com/2022/02/'>February 2022</a></li> <li><a href='https://lexariabioscience.com/2022/01/'>January 2022</a></li> <li><a href='https://lexariabioscience.com/2021/12/'>December 2021</a></li> <li><a href='https://lexariabioscience.com/2021/11/'>November 2021</a></li> <li><a href='https://lexariabioscience.com/2021/10/'>October 2021</a></li> <li><a href='https://lexariabioscience.com/2021/09/'>September 2021</a></li> <li><a href='https://lexariabioscience.com/2021/07/'>July 2021</a></li> <li><a href='https://lexariabioscience.com/2021/06/'>June 2021</a></li> <li><a href='https://lexariabioscience.com/2021/05/'>May 2021</a></li> <li><a href='https://lexariabioscience.com/2021/04/'>April 2021</a></li> <li><a href='https://lexariabioscience.com/2021/03/'>March 2021</a></li> <li><a href='https://lexariabioscience.com/2021/02/'>February 2021</a></li> <li><a href='https://lexariabioscience.com/2021/01/'>January 2021</a></li> <li><a href='https://lexariabioscience.com/2018/08/'>August 2018</a></li> <li><a href='https://lexariabioscience.com/2018/02/'>February 2018</a></li> <li><a href='https://lexariabioscience.com/2018/01/'>January 2018</a></li> <li><a href='https://lexariabioscience.com/2017/09/'>September 2017</a></li> <li><a href='https://lexariabioscience.com/2017/08/'>August 2017</a></li> <li><a href='https://lexariabioscience.com/2014/12/'>December 2014</a></li> </ul> </aside></aside> </div> </div> </div> <footer id="colophon" class="site-footer "> <div class="footer_inner_wrapper footer ts-bg ts-bgcolor-grey ts-bgimage-no"> <div class="site-footer-bg-layer ts-bg-layer"></div> <div class="site-footer-w"> <div class="footer-rows"> <div class="footer-rows-inner"> <div id="first-footer" class="sidebar-container first-footer ts-bg ts-bgcolor-grey ts-textcolor-dark ts-bgimage-no" role="complementary"> <div class="first-footer-bg-layer ts-bg-layer"></div> <div class="container"> <div class="first-footer-inner"> <div class="row multi-columns-row"> <div class="widget-area col-xs-12 col-sm-4 col-md-4 col-lg-4 first-widget-area"> <aside id="block-11" class="widget-odd widget-5 widget widget_block widget_media_image"> <figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" src="https://lexariabioscience.com/wp-content/uploads/2022/03/Lexaria_Bioscience_Logo_Dark_WEB.png" alt="" class="wp-image-7760" width="180" height="95" srcset="https://lexariabioscience.com/wp-content/uploads/2022/03/Lexaria_Bioscience_Logo_Dark_WEB.png 418w, https://lexariabioscience.com/wp-content/uploads/2022/03/Lexaria_Bioscience_Logo_Dark_WEB-300x158.png 300w" sizes="auto, (max-width: 180px) 100vw, 180px" /></figure> </aside><aside id="block-2" class="widget-even widget-6 widget widget_block widget_text"> <p>Lexaria Bioscience Corp. (NASDAQ:LEXX) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.</p> </aside> </div> <div class="widget-area col-xs-12 col-sm-4 col-md-4 col-lg-4 first-widget-area"> <aside id="block-35" class="widget-odd widget-5 widget widget_block widget_text"> <p><a href="tel:+12507656424">250.765.6424</a><br><a href="/cdn-cgi/l/email-protection#8fe6e1e9e0cfe3eaf7eefde6eeede6e0fcece6eae1eceaa1ece0e2"><span class="__cf_email__" data-cfemail="650c0b030a2509001d04170c04070c0a16060c000b06004b060a08">[email protected]</span></a></p> </aside><aside id="block-37" class="widget-even widget-6 widget widget_block widget_text"> <p><b>Canadian Operations</b><br>#100-740 McCurdy Road<br>Kelowna, BC, V1X2P7<br><br><strong>US Operations</strong><br>105 Peach State Court, Suite A<br>Tyrone, GA 30290</p> </aside><aside id="block-31" class="widget-odd widget-7 widget widget_block widget_text"> <p><a href="https://lexariabioscience.com/privacy-policy/">Privacy Policy</a></p> </aside><aside id="block-13" class="widget-even widget-8 widget widget_block"><p><ul id="" class="cnss-social-icon " style="text-align:left;"><li class="cn-fa-facebook cn-fa-icon " style="display:inline-block;"><a class="" target="_blank" href="https://www.facebook.com/lexariabioscience" title="facebook" style="width:28px;height:28px;padding:5px 0;margin:6px;color: #ffffff;border-radius: 0%;"><i title="facebook" style="font-size:18px;" class="fab fa-facebook"></i></a></li><li class="cn-fa-twitter cn-fa-icon " style="display:inline-block;"><a class="" target="_blank" href="https://twitter.com/lexariabiocorp" title="twitter" style="width:28px;height:28px;padding:5px 0;margin:6px;color: #ffffff;border-radius: 0%;"><i title="twitter" style="font-size:18px;" class="fab fa-twitter"></i></a></li><li class="cn-fa-linkedin cn-fa-icon " style="display:inline-block;"><a class="" target="_blank" href="https://www.linkedin.com/company/lexaria-bioscience/" title="linkedin" style="width:28px;height:28px;padding:5px 0;margin:6px;color: #ffffff;border-radius: 0%;"><i title="linkedin" style="font-size:18px;" class="fab fa-linkedin"></i></a></li></ul></p> </aside> </div> <div class="widget-area col-xs-12 col-sm-4 col-md-4 col-lg-4 first-widget-area"> <aside id="block-10" class="widget-even widget-2 widget widget_block widget_text"> <p><strong>General Disclaimer:</strong><br>No statement in this web site has been evaluated by the Food and Drug Administration (FDA). Furthermore, none of the statements in this web site should be construed as dispensing medical advice or making claims regarding the cure of diseases…<br><br><a href="https://lexariabioscience.com/general-disclaimer/">Read More</a></p> </aside> </div> </div> </div> </div> </div> </div> </div> <div id="bottom-footer-text" class="bottom-footer-text ts-bottom-footer-text site-info ts-bg ts-bgcolor-transparent ts-textcolor-dark ts-bgimage-no"> <div class="bottom-footer-bg-layer ts-bg-layer"></div> <div class="container"> <div class="bottom-footer-inner"> <div class="row multi-columns-row"> <div class="col-xs-12 col-sm-12 ts-footer2-left "> Copyright © 2024 <a href="https://lexariabioscience.com">Lexaria Bioscience</a>. All rights reserved. </div> </div> </div> </div> </div> </div> </div> </footer> </div> </div>  <a id="totop" href="#top"><i class="ts-labtechco-icon-angle-up"></i></a> <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script> window.RS_MODULES = window.RS_MODULES || {}; window.RS_MODULES.modules = window.RS_MODULES.modules || {}; window.RS_MODULES.waiting = window.RS_MODULES.waiting || []; window.RS_MODULES.defered = true; window.RS_MODULES.moduleWaiting = window.RS_MODULES.moduleWaiting || {}; window.RS_MODULES.type = 'compiled'; </script> <script>(function(){var s=document.createElement('script');e = !document.body ? document.querySelector('head'):document.body;s.src='https://acsbapp.com/apps/app/dist/js/app.js';s.defer=true;s.onload=function(){acsbJS.init({ statementLink : '', feedbackLink : '', footerHtml : '', hideMobile : false, hideTrigger : false, language : 'en', position : 'right', leadColor : '#3a5dae', triggerColor : '#3a5dae', triggerRadius : '50%', triggerPositionX : 'right', triggerPositionY : 'top', triggerIcon : 'people', triggerSize : 'medium', triggerOffsetX : 15, triggerOffsetY : 50, mobile : { triggerSize : 'small', triggerPositionX : 'left', triggerPositionY : 'center', triggerOffsetX : 0, triggerOffsetY : 0, triggerRadius : '50%' } }); }; e.appendChild(s);}());</script> <script> var _paq = _paq || []; _paq.push(['trackPageView']); (function () { var u = "https://stats1.wpmudev.com/"; _paq.push(['setTrackerUrl', u + 'track/']); _paq.push(['setSiteId', '102684']); var d = document, g = d.createElement('script'), s = d.getElementsByTagName('script')[0]; g.type = 'text/javascript'; g.async = true; g.defer = true; g.src = 'https://stats.wpmucdn.com/analytics.js'; s.parentNode.insertBefore(g, s); })(); </script> <script> jQuery('#popmake-8310').find('.ts-vc_btn3').click(function() { document.cookie = "pum-8310=true;"; }); </script><link rel='stylesheet' id='rs-plugin-settings-css' href='https://lexariabioscience.com/wp-content/plugins/revslider/public/assets/css/rs6.css?ver=6.5.15' media='all' /> <style id='rs-plugin-settings-inline-css'> #rs-demo-id {} </style> <script src="https://lexariabioscience.com/wp-includes/js/jquery/ui/core.min.js?ver=1.13.3" id="jquery-ui-core-js"></script> <script src="https://lexariabioscience.com/wp-includes/js/jquery/ui/mouse.min.js?ver=1.13.3" id="jquery-ui-mouse-js"></script> <script src="https://lexariabioscience.com/wp-includes/js/jquery/ui/sortable.min.js?ver=1.13.3" id="jquery-ui-sortable-js"></script> <script src="https://lexariabioscience.com/wp-includes/js/dist/hooks.min.js?ver=4d63a3d491d11ffd8ac6" id="wp-hooks-js"></script> <script src="https://lexariabioscience.com/wp-includes/js/dist/i18n.min.js?ver=5e580eb46a90c2b997e6" id="wp-i18n-js"></script> <script id="wp-i18n-js-after"> /* <![CDATA[ */ wp.i18n.setLocaleData( { 'text direction\u0004ltr': [ 'ltr' ] } ); /* ]]> */ </script> <script src="https://lexariabioscience.com/wp-content/plugins/contact-form-7/includes/swv/js/index.js?ver=6.0" id="swv-js"></script> <script id="contact-form-7-js-before"> /* <![CDATA[ */ var wpcf7 = { "api": { "root": "https:\/\/lexariabioscience.com\/wp-json\/", "namespace": "contact-form-7\/v1" } }; /* ]]> */ </script> <script src="https://lexariabioscience.com/wp-content/plugins/contact-form-7/includes/js/index.js?ver=6.0" id="contact-form-7-js"></script> <script src="https://lexariabioscience.com/wp-content/plugins/revslider/public/assets/js/rbtools.min.js?ver=6.5.15" defer async id="tp-tools-js"></script> <script src="https://lexariabioscience.com/wp-content/plugins/revslider/public/assets/js/rs6.min.js?ver=6.5.15" defer async id="revmin-js"></script> <script src="https://lexariabioscience.com/wp-content/themes/labtechco/libraries/perfect-scrollbar/perfect-scrollbar.jquery.min.js?ver=6.7.1" id="perfect-scrollbar-js"></script> <script src="https://lexariabioscience.com/wp-content/themes/labtechco/libraries/select2/select2.min.js?ver=6.7.1" id="ts-select2-js"></script> <script src="https://lexariabioscience.com/wp-content/plugins/js_composer/assets/lib/vendor/node_modules/isotope-layout/dist/isotope.pkgd.min.js?ver=7.7.2" id="isotope-js"></script> <script src="https://lexariabioscience.com/wp-content/themes/labtechco/libraries/jquery-mousewheel/jquery.mousewheel.min.js?ver=6.7.1" id="jquery-mousewheel-js"></script> <script src="https://lexariabioscience.com/wp-content/plugins/js_composer/assets/lib/vendor/node_modules/flexslider/jquery.flexslider-min.js?ver=7.7.2" id="flexslider-js"></script> <script src="https://lexariabioscience.com/wp-content/themes/labtechco/libraries/sticky-kit/jquery.sticky-kit.min.js?ver=6.7.1" id="sticky-kit-js"></script> <script src="https://lexariabioscience.com/wp-content/themes/labtechco/libraries/slick/slick.min.js?ver=6.7.1" id="slick-js"></script> <script src="https://lexariabioscience.com/wp-content/plugins/js_composer/assets/lib/vendor/prettyphoto/js/jquery.prettyPhoto.min.js?ver=7.7.2" id="prettyphoto-js"></script> <script src="https://lexariabioscience.com/wp-content/plugins/js_composer/assets/js/dist/js_composer_front.min.js?ver=7.7.2" id="wpb_composer_front_js-js"></script> <script id="labtechco-script-js-extra"> /* <![CDATA[ */ var ts_labtechco_js_vars = {"ts_breakpoint":"1200","ajaxurl":"https:\/\/lexariabioscience.com\/wp-admin\/admin-ajax.php"}; /* ]]> */ </script> <script src="https://lexariabioscience.com/wp-content/themes/labtechco/js/scripts.min.js?ver=1.0" id="labtechco-script-js"></script> <script></script> <script> jQuery(document).ready(function() { var target = document.querySelector('.site-header-menu-inner'); if (target) { var observer = new MutationObserver(function(mutationsList) { mutationsList.forEach(function(mutation) { if (mutation.type === 'attributes' && mutation.attributeName === 'class') { if (jQuery(target).hasClass('is_stuck')) { // console.log('.is_stuck class added'); jQuery('.investor-menu').addClass('sticky-nav'); } else { // console.log('.is_stuck class removed'); jQuery('.investor-menu').removeClass('sticky-nav'); } } }); }); observer.observe(target, { attributes: true }); } });</script>   <script> // JavaScript to toggle the menu document.addEventListener('DOMContentLoaded', function() { var hamburger = document.querySelector('.hamburger'); var menu = document.querySelector('.investor-menu ul.menu'); hamburger.addEventListener('click', function() { menu.classList.toggle('active'); }); }); </script>  </body> </html>